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Ampr Ampicillin resistance gene 
AKT3 V-Akt Murine Thymoma Viral Oncogene Homolog 3 
ATCC American Type Culture Collection 
APC Anaphase Promoting Complex 
AURK Aurora Kinase 
BCL2  B-Cell Lymphoma 2 
BCL-XL  B-Cell Lymphoma extra large 
bp Base pair 
BRAF  Murine Sarcoma Viral (V-Raf) Oncogene Homolog B1 
BSA Bovine Serum Albumin 
cDNA Complementary DNA 
CHX Cycloheximide 
c-KIT     V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral 
Oncogene Homolog 
CMV Cytomegalovirus 
c-Myc V-Myc Avian Myelocytomatosis Viral Oncogene 
Homolog 
Crk V-Crk Avian Sarcoma Virus CT10 Oncogene Homolog 
CTLA4     Cytotoxic T-lymphocyte antigen 4 
C3G Rap Guanine Nucleotide Exchange Factor (GEF) 1 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dsDNA Double-stranded DNA 
DSB  DNA double-strand break 
DTIC            Dacarbazine 
EGF Epidermal Growth Factor 
EMEA European Agency for the Evaluation of Medicinal 
Products 
ERK   Mitogen-Activated Protein Kinase 
ER Endoplasmic Reticulum 
EDTA Ethylene Diamine Tetraacetic Acid 
FAK Focal Adhesion Kinase 
FBS  Fetal Calf Serum 
FDA Food and Drug Administration 
FF  Foreskin Fibroblast 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
GFP Green fluorescent protein 
Grb10 Growth Factor Receptor-Bound Protein 10 
Grb2  Growth Factor Receptor-Bound Protein 
HAUSP/ USP7 Herpes virus-associated ubiquitin-specific protease 
HA Hemagglutinin 
HIV-1 Human Immunodeficiency Virus 1 
HRP Horseradish Peroxidase 
IC50 Half maximal inhibitory concentration 
IGF Insulin-like Growth Factor 
IGF-1 Insulin-like Growth Factor 1 
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IGFBP IGF Binding Proteins 
IGF-1R Insulin-like Growth Factor 1 Receptor 
IGF-2R Insulin-like Growth Factor 2 Receptor 
IR Insulin Receptor 
IRS-1/2 Insulin-Receptor Substrate1/2 
kDa Kilo dalton 
kb Kilo base 
LB medium Lysogeny Broth medium 
MAPK Mitogen-Activated Protein Kinase 
MEK1/2 Mitogen-Activated Protein Kinase Kinase 1/2 
miR-30 MicroRNA-30 
ml Millilitre 
mRNA Messenger RNA 
mTOR  Mechanistic Target Of Rapamycin (Serine/Threonine 
Kinase) 
MUH 4-Methylumbelliferylheptanoate 
M6P  Mannose-6-Phosphate 
NEDD4 Neural Precursor Cell Expressed, Developmentally 
Down-Regulated 4, E3 Ubiquitin Protein Ligase 
NEJM New England Journal of Medicine  
NRAS  Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog 
dNTP Desoxyribonucleosid-5´-triphosphate 
nt Nucleotides 
PBS Phosphate Buffered Saline 
PDK Phosphoinositide-Dependent Kinases 
PDK1/2 Phosphoinositide-Dependent Kinases 1/2 
PD-1  Programmed Death protein-1 
PD-L1 Programmed Death-Ligand 1 
PFS     Progression Free Survival 
PFA Para-formaldehyde 
PGK Phosphoglycerate Kinase 
PI Propidium Iodide 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PIP3 Phosphatidyl Inositol-3,4,5-triphosphate 
PI3K  Phosphatidyl Inositol-3 Kinase 
PKC  Protein Kinase C 
PLK1  Polo-Like Kinase 1 
PPP  Picropodophyllin 
PPGK  Murine Phosphoglycerate Kinase (PGK) promoter 
PSA Prostate-Specific Antigen 
PTEN Phosphate and Tensin homologue 
PTPs Tensin/auxilin and protein Tyrosine Phosphatases 
Puror Puromycin resistance gene 
PVDF Polyvinylidene difluoride 
qRT-PCR Quantitative Real-Time PCR 
Rap1    Ras-related protein 1 
RAS Rat sarcoma 
RGP Radial Growth Phase  
RNA Ribonucleic Acid 
rpm Revolutions Per Minute 
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RPMI Roswell Park Memorial Institute  
RT Room Temperature 
RTK  Receptor Tyrosine Kinases 
shRNA Short hairpin RNA 
SHC  Src Homology/Collagen 
siRNA Small interfering RNA 
SOCS  Suppressors Of Cytokine Signaling 
SOS Son Of Sevenless 
STATs Signal Transducers and Activators of Transcription 
TBE Tris Borate EDTA 
TBST Tris Buffered Saline with Tween20 
TE Tris-EDTA 
TET Tetracycline 
TETO tet operator  
TEP1  TGF-β regulated and Epithelial cell enriched 
Phosphatase 
TRAIL  Tumor-necrosis-factor-Related Apoptosis-Inducing 
Ligand 
VGP Vertical-Growth Phase 
VSV-G  Vesicular Stomatitis indiana Virus protein G 
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1  Introduction 
Melanoma is a malignant tumor, which originates from benign melanocytes (Slominski, Tobin 
et al. 2004; Gray-Schopfer, Wellbrock et al. 2007). Due to the production of melanin, the 
majority of melanomas are black or brown. It predominantly occurs in skin, but is also found in 
some other body locations as in the bowel and in the eye. There are four basic types of 
melanoma, which differ in frequency and location in the body. Superficial spreading 
melanoma, nodular melanoma, and lentigo maligna melanomas make up 90% of all 
diagnosed malignant melanomas. Acral lentiginous melanoma and a few very rare types 
together make up the other 10% (Clark 1967; Reed 1976). Melanoma is the least common 
but the most deadly skin cancer. Although it´s accounting for only about 4% of all cases, it 
results in 80% of skin cancer deaths due to its potential to metastasize early in tumor 
development (Miller and Mihm 2006; Gray-Schopfer, Wellbrock et al. 2007). 
1.1 Incidence and risk factors 
At the present time, the incidence of melanoma is doubling every 10 to 20 years (Sandru, 
Voinea et al. 2014). For young people aged between 25 and 49 the mortality rate increases in 
the magnitude of 2-3% per year in some North and West European countries and up to 8% in 
Spain. For old people the mortality increase varied in men above age 70 between 2.7% 
(Netherlands) and 7.5% (Spain) and in elderly women between 0.8% (Norway) and 7.7% 
(Spain) (de Vries, Bray et al. 2003). 
Risk factors for melanoma development can be subdivided into genetic and environmental 
with interaction between the two. About 5% of all invasive cutaneous melanomas run in a 
familial setting with two or more close relatives affected. This observation indicates that low 
prevalence/high penetrance genes are responsible for a small minority of melanoma patients 
(MacKie, Hauschild et al. 2009). In addition, the incidence of melanoma increases at higher 
rates in Australia and North America. This geographic pattern reflects that ultraviolet light 
exposure is one of the primary causes of melanoma development. By this, people with white 
skin are more susceptible to UV-induced DNA damage (World Cancer Report 2014). 
Moreover, high counts of benign melanocytic naevi, the effect of female sex hormones, 
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socioeconomic status, occupation, exposure to pesticides and ingestion of therapeutic drugs 
including immunosuppressive and non-steroidal anti-inflammatory drugs are considered to 
be risk factors for melanoma development (MacKie, Hauschild et al. 2009). 
1.2 Prognosis and therapy 
1.2.1 Prognosis 
Factors that affect prognosis are tumor thickness in millimeters (Breslow's depth), depth 
related to skin structures (Clark level), type of melanoma, presence of ulceration, presence of 
lymphatic/perineural invasion, presence of tumor-infiltrating lymphocytes (if present, 
prognosis is better), location of lesion, presence of satellite lesions, and presence of regional 
or distant metastasis (Homsi, Kashani-Sabet et al. 2005). Thick melanomas are associated 
with a worse prognosis. It´s generally considered that the cancer is incurable when distant 
metastases occur, especially metastases in brain, bone and liver, and the five-year survival 
rate is less than 10% (Balch, Buzaid et al. 2001).  
1.2.2  Therapy 
1.2.2.1 Surgical treatment 
The majority of melanoma patients have early stage disease, with 62.6% presenting with 
stage 0 or I disease, and an additional 23.1% with stage II disease (Chang, Karnell et al. 
1998). The standard therapy for localized melanoma is surgical resection, which can achieve 
a high cure rate. Moreover, recent studies showed that advanced-stage melanoma patients 
get a benefit from surgical excision (Young, Martinez et al. 2006). In a phase 2 trial, complete 
resection for stage IV melanoma prolonged overall survival with a median survival of 21 
months (Sosman, Moon et al. 2011).  
1.2.2.2 Chemotherapy 
Chemotherapy has been the standard systemic treatment for patients with disseminated 
melanoma for many years. There are few cytotoxic agents that have been approved for the 
treatment of malignant melanoma. As one of the only Food and Drug Administration 
(FDA)-approved cytotoxic agents for the treatment of metastatic melanoma, Dacarbazine 
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(DTIC) has limited benefit in the adjuvant treatment of melanoma (Eigentler, Caroli et al. 2003; 
Bedikian, DeConti et al. 2011; Chapman, Hauschild et al. 2011). Although combination 
chemotherapy regimens with or without cytokines (biochemotherapy) or tamoxifen increased 
response rates, it has not been demonstrated to be superior to monotherapy with DTIC in 
terms of survival (Eggermont and Schadendorf 2009). Carmustine, paclitaxel (Taxol), 
temozolomide and cisplatin, among others have been tested in limited clinical studies, but all 
of these therapies provide little benefit to overall patient survival (Tarhini and Agarwala 2006; 
Gray-Schopfer, Wellbrock et al. 2007). 
1.2.2.3 Immunotherapy  
In parallel with the development of BRAF inhibitors there are advances in immunotherapy. 
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) expressed on the surface of activated T cells 
limits the development of antigen specific immune responses and prevents uncontrollable 
overactivation of immune effector mechanisms (Melero, Hervas-Stubbs et al. 2007). 
Ipilimumab is an anti–cytotoxic CTLA-4 antibody, which acts to upregulate antitumor 
immunity. Two phase III randomized clinical trials demonstrate that it significantly improved 
median overall survival (Hodi, O'Day et al. 2010; Robert, Thomas et al. 2011). In long-term 
follow up of earlier studies three separate trials achieved 5-year survival rates of 13, 23 and 
25%, respectively (Prieto, Yang et al. 2012). 
The programmed death protein-1 (PD-1) is an inhibitory co-receptor, which is expressed on 
activated T cells or B cells. Its ligand B7-H1, programmed death-ligand 1 (PD-L1), mediates 
PD-1-dependent immunosuppression. The interaction of PD-L1 expressed on cancer cells or 
tumor stromal cells with PD-1 on the surface of T cells facilitates tumor escape from antitumor 
immunity (Blank and Mackensen 2007; Jin, Ahmed et al. 2011). FDA has approved two 
anti-PD-1 antibodies, pembrolizumab and nivolumab, targeting the PD-1 receptors for the 
treatment of metastatic melanoma in 2014. Compared with chemotherapy, superior efficacy 
of nivolumab has been demonstrated in previously untreated patients with wild-type BRAF 
tumors (Robert, Long et al. 2015). Similar effects are seen in patients with either mutant or 
wild-type BRAF tumors after progression during ipilimumab therapy and in patients with 
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tumors positive for BRAF mutation after progression during treatment with a BRAF inhibitor 
(Weber, D'Angelo et al. 2015). 
Ipilimumab is considered to be able to prolong overall survival, while nivolumab produces 
durable tumor regression in patients with melanoma. Based on their distinct immunologic 
mechanisms of action and supportive preclinical data, trials of the combination of nivolumab 
with ipilimumab in patients with advanced melanoma were conducted. Recently a 
randomized, double blind, phase 3 study showed that among previously untreated patients 
with metastatic melanoma progression free survival (PFS) was significantly prolonged by 
treatment with nivolumab alone or combined with ipilimumab than ipilimumab alone. In 
patients with PD-L1–negative tumors, nivolumab combined with ipilimumab was more 
effective than either agent alone (Larkin, Hodi et al. 2015). 
1.2.2.4 Targeted therapy with signal transduction inhibitors 
In melanoma there are three well-defined driver oncogenes: BRAF, NRAS and c-KIT, which 
activate predominantly the MAPK signaling pathway (Swick and Maize 2012). 
1.2.2.4.1 BRAF inhibitor 
Somatic mutations in BRAF exist in 40-50% of metastatic melanoma (Maldonado, Fridlyand 
et al. 2003; Curtin, Fridlyand et al. 2005). In the vast majority of mutations the valine at the 
600th amino acid position is substituted by glutamine in 80% of cases (V600E) (Rubinstein, 
Sznol et al. 2010; Lovly, Dahlman et al. 2012). PLX4032 (vemurafenib) specifically targets 
the BRAFV600 mutation and in a multi-center phase II trial of patients with this mutation 
PLX4032 resulted in significantly longer median overall survival than chemotherapeutic 
agents (Sosman, Kim et al. 2012). PLX4032 was approved by the FDA in 2011 and by 
European Agency for the Evaluation of Medicinal Products (EMEA) in 2012 for first-line 
treatment of patients with BRAFV600-mutation positive melanoma. Although the evidence for 
clinical benefit with PLX4032 is compelling, resistance has posed a major obstacle 
(Johannessen, Boehm et al. 2010; Nazarian, Shi et al. 2010; Villanueva, Vultur et al. 2010). 
Additionally, an increased incidence of cutaneous squamous cell carcinoma has been 
associated with PLX4032 treatment. The paradoxical MAPK pathway activation rather than 
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PLX4032 has been identified as the culprit (Su, Viros et al. 2012). Dabrafenib (GSK2118436, 
GlaxoSmithKline) is another specific BRAFV600 inhibitor, which has been found to have 
preclinical activity against melanoma in cell lines and xenografts. Early phase trials also 
demonstrated that it has superior efficacy against BRAF mutant melanoma (Falchook, Long 
et al. 2012). Objective responses to it were seen in 53-69% of patients with BRAFV600E or V600K 
mutations. Its similarity to PLX4032 is timing of responses and development of resistance, 
but its side-effect profile is different from PLX4032 in several ways. Compared with PLX4032, 
it appeared to result in a lower incidence of cutaneous squamous cell carcinomas or 
keratoacanthomas (6-19%) (Johnson and Sosman 2013). 
1.2.2.4.2 MEK inhibitor  
The blockade of MEK in the MAPK pathway downstream from BRAF mechanistically could 
have activity in both, melanoma with BRAF mutations and NRAS mutations. Trametinib is a 
highly specific inhibitor of MEK1/ 2 and best evaluated in the clinic (Infante, Fecher et al. 
2012). A phase III trial demonstrated that in 322 patients with melanoma positive for 
BRAFV600E or V600K mutations, the median duration of PFS was 4.8 and 1.5 months, the 
6-month overall survival rate was 81 and 67%, and objective response rates were 22 and 8% 
for trametinib and chemotherapy, respectively (Flaherty, Robert et al. 2012).  
1.2.2.4.3 Combination of Dabrafenib and Trametinib 
It´s postulated that bypass activation of the MAPK pathway was considered to be an 
important mechanism of drug resistance, hence complete abrogation of the MAPK pathway 
by simultaneous administration of BRAF and MEK-targeting agents was hoped to prevent or 
delay the development of acquired resistance to BRAF inhibitors. However recent 
publications showed that the emergence of resistance was delayed only 0.5 to 3.7 months by 
such combinations in terms of PFS in the New England Journal of Medicine (NEJM) reports 
(Larkin, Ascierto et al. 2014; Long, Stroyakovskiy et al. 2014; Robert, Long et al. 2015). The 
basic implications of these outcomes have been revisited, and the underlying biology is 
needed to be investigated in future. 
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1.2.2.4.4  c-KIT inhibitor 
Somatic mutations in KIT, the V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene 
Homolog, are more often found in primary melanoma tumors on acral surfaces (soles of the 
feet, nail beds) or in mucosae (10-20%) (Satzger, Schaefer et al. 2008; Torres-Cabala, Wang 
et al. 2009). Imatinib is a kinase inhibitor, which inhibits a range of tyrosine kinases including 
c-KIT and is currently FDA approved for gastrointestinal stromal tumors (Ugurel, Hildenbrand 
et al. 2005). Two phase II trials have been completed using imatinib in KIT mutant melanoma. 
The data indicates an objective response rate of 16% and 23%, and a median PFS of 3 and 
3.5 months, respectively, for the two separate trials (Carvajal, Antonescu et al. 2011). 
1.3 Biology of Melanoma 
1.3.1 Biologic Events and Molecular Changes in the Progression of Melanoma 
It is believed that the development of melanoma is involved in a multi-step process, due to 
complex interactions between genetic and environmental influences. Melanomas are 
histologically classified into five distinct stages: common acquired and congenital nevi 
without dysplasia, dysplastic nevi, radial-growth phase (RGP) melanoma, vertical-growth 
phase (VGP) melanoma and metastatic melanoma (Fig.1). The first phenotypic change in 
melanocytes is the development of benign nevi, in which the activation of oncogenic 
pathways disrupts the control of growth in melanocytes, but the progression of nevus to 
cancer is rare, probably due to oncogene-induced cell senescence. Next cytologic atypia 
develops in dysplastic nevi, probably arising from preexisting benign nevi or as new lesions. 
At this stage of progression, cumulative mutations result in dysregulation of cell growth, DNA 
repair, and the susceptibility to cell death. Compared with RGP melanoma growing laterally 
and largely confined to the epidermis, VGP melanoma invades the upper layers of the 
epidermis and penetrates into the underlying dermis and subcutaneous tissue, where it forms 
expansible nodules of malignant cells. The transition from RGP to VGP melanoma is 
considered to be the crucial step in the evolution to malignant melanoma (Miller and Mihm 
2006). 
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Figure 1:  Biologic Events and Molecular Changes in the Progression of Melanoma (Miller and Mihm 
2006).  
1.3.2 Signaling in melanoma 
1.3.2.1  The RAS/RAF/MEK/ERK pathway 
The mitogen-activated protein kinase (MAPK) pathway is evolutionarily conserved. It is 
composed of different kinases linking extracellular signals to the machinery that controls 
fundamental cellular processes such as growth, proliferation, differentiation, migration and 
apoptosis. 
A wide variety of receptors involved in growth and differentiation including receptor tyrosine 
kinases (RTKs), integrins, and ion channels are able to activate the MAPK pathway. The 
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receptors are linked by a set of adaptors (Shc, Grb2, Crk, etc.) to a guanine nucleotide 
exchange factor (SOS, C3G, etc.), which transduces the signal to small GTP-binding proteins 
(RAS, Rap1). Sequently they activate the core unit of the cascade, which is composed of Raf, 
MEK1/2 and ERK. D-type cyclins and various transcription factors are phosphorylated by an 
activated ERK dimer, and further regulate cell survival and proliferation (Pimienta and 
Pascual 2007; Raman, Chen et al. 2007; Shaul and Seger 2007). Abnormal activation of the 
MAPK pathway impairs the cell cycle control, which is essential for melanoma development.  
In melanoma the activation of this pathway is mainly due to somatic mutations of NRAS, 
which are associated with about 15% of melanomas, or BRAF, which are associated with 
about 50% of melanomas. These mutations appear in a mutually exclusive manner (Albino, 
Nanus et al. 1989; Brose, Volpe et al. 2002; Omholt, Platz et al. 2003).  
1.3.2.2  PI3K Pathway 
Phosphatidylinositol-3 kinases (PI3Ks) is composed of a lipid kinase family characterized by 
their ability to phosphorylate an inositol ring 3'-OH group in inositol phospholipids to generate 
the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and 
Phosphatidylinositol-4,5-bisphosphate (PIP2). RTK activation leads to production of PIP3 
and PIP2 by PI3K at the inner side of the plasma membrane. AKT interacts with these 
phospholipids, which causes its translocation to the inner membrane, where it is 
phosphorylated and activated by phosphoinositide-dependent kinases 1/2 (PDK1/2). 
Activated AKT can phosphorylate numerous substrates that regulate cell survival, cell cycle 
progression and cellular growth (Bellacosa, Kumar et al. 2005; Madhunapantula and 
Robertson 2009). This signaling is inhibited by the tumor suppressor phosphate and tensin 
homologue (PTEN) (Keniry and Parsons 2008; Aguissa-Toure and Li 2012). 
1.3.2.3 AKT 
Overexpression and hyperactivation of AKT, the V-Akt Murine Thymoma Viral Oncogene 
Homolog 3, are present at 60-70% of sporadic melanomas (Stahl, Sharma et al. 2004). 
Significant phosphorylation of AKT3 was registered in 17%, 43%, 49% and 77% of biopsies 
from normal nevi, dysplastic nevi, primary melanoma and melanoma metastases, 
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respectively. It´s a poor prognostic factor for patients with melanoma less than 1.5 mm 
thickness as the level of expression of phosphorylated AKT3 is increased (Dai, Martinka et al. 
2005). 
1.3.2.4 PTEN 
1.3.2.4.1 Structure  
The PTEN gene, also known as TGF-β-regulated and epithelial cell enriched phosphatase 
(TEP1), is a tumor suppressor gene, which is isolated and identified by three laboratories in 
1997. The human genomic PTEN is located on chromosome 10q23.3. It consists of 9 exons 
and 8 introns, and encodes a 5.5 kb mRNA that defines a 403 amino-acid open reading frame. 
PTEN is a 53 kDa protein with high homology to tensin/auxilin and protein tyrosine 
phosphatases (PTPs) (Li and Sun 1997; Li, Yen et al. 1997; Steck, Pershouse et al. 1997; 
Lee, Yang et al. 1999; Waite and Eng 2002). Studies of the crystal structure of PTEN have 
revealed that the human PTEN protein is composed of four functional modules: (1) N- 
terminal residue of the phosphatase domain carrying the conserved phosphatase motif 
HCSSGSSR. This domain is highly homologous to the catalytic domains of tyrosine 
phosphatase and serine/threonine phosphatase, indicating that it has ability to 
dephosphorylate tyrosine and serine/threonine residues. Most of missense mutations 
involved in human tumors and Cowden syndrome have been found in the phosphatase 
domain (Maehama, Taylor et al. 2001); 
HTTP://www.hgmd.cf.ac.uk/ac/gene.php?gene_PTEN) and biochemical analysis have 
confirmed that such mutations lead to a robust decrease in the phosphatase activity (Han, 
Kato et al. 2000; Koul, Jasser et al. 2002); (2) C- terminal residue of the C2 domain combines 
with phospholipids in a Ca2+ - independent manner, and by this PTEN is localized in cell 
membranes, where it´s able to mediate an signal transduction. One study indicated that the 
modulation of molecular interaction between the phosphatase and C2 domains by 
phosphorylation of the C- terminal tail of PTEN dictates the percentage of 
membrane-associated PTEN and the level of PIP3 (Rahdar, Inoue et al. 2009); (3) The PDZ 
protein- binding domain and two PEST sequences (rich in Proline (P), Glutamic acid (E), 
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Serine (S) and Threonine (T)) in the tail region consist of multiple phosphorylation sites 
(Ser-370, Ser-380, Thr-382, Thr-383, and Ser-385) indispensable for PTEN protein stability. 
In fact, C-terminal deletion and phosphorylation-resistant mutants are quite unstable and 
rapidly degraded in cells (Vazquez, Ramaswamy et al. 2000; Torres and Pulido 2001; Birle, 
Bottini et al. 2002; Miller, Lou et al. 2002). 
 
Figure 2: PTEN protein structure. PTEN protein is composed of an N-terminal PIP2-binding motif, a 
phosphatase domain, a C2 domain, a C-terminal tail containing PEST sequences, and a PDZ interaction motif 
at the end. PTEN's phosphatase activity is disrupted by naturally occurring mutations on the phosphatase 
domain: C124S mutation abrogates both lipid and protein phosphatase activity, and G129E mutation abrogates 
only lipid phosphatase but not protein phosphatase activity (Zhang and Yu 2010). 
1.3.2.4.2 Biological function  
PTEN is a tumor suppressor gene. Studies over the past 10 years have revealed that a 
variety of cellular signal transduction pathways or molecules are regulated by PTEN, and 
form a complex network system to control proliferation, apoptosis, migration, adhesion and 
genetic stability. PTEN can dephosphorylate not only lipids but also proteins.  Also, it can 
regulate signal transduction by both phosphatase- dependent and independent manners. 
PTEN is different from most tumor suppressor genes, and can function in the nucleus as well 
as in the cytoplasm. It has been shown that PTEN is associated with organelles such as the 
endoplasmic reticulum (ER), the mitochondria or the nucleus, and is secreted. PTEN activity 
can be modulated by mutations, epigenetic silencing, transcriptional repression, aberrant 
protein localization, and post-translational modifications. Also, its stability and function can be 
highly impacted by its precise intracellular localization (Tamguney and Stokoe 2007; 
Chetram and Hinton 2012). 
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The negative regulation on PI3K/AKT pathway by PTEN has been deeply studied. In the 
cytoplasm dephosphorylation of PIP3 to PIP2 by PTEN reverses the action of PI3K and 
hampers all downstream functions controlled by the AKT/mTOR axis, such as cycle 
progression, induction of cell death, transcription, translation, stimulation of angiogenesis, 
and stem cell self-renewal (Maehama and Dixon 1998). Additionally, cytoplasmic PTEN can 
regulate epidermal growth factor (EGF) signaling by inhibiting phosphorylation of SHC 
adaptor proteins, which in turn suppress activation of the MAPK pathway (Gu, Tamura et al. 
1998). Finally, PTEN can also regulate the activity of focal adhesion kinases (FAKs) through 
dephosphorylation and other membrane channels to control cell migration, stretching and 
adhesion (Tamura, Gu et al. 1999).  
Like other tumor suppressor genes, nuclear PTEN has important biological functions. The 
level of functional PTEN in the nucleus is regulated through dynamic changes in its 
ubiquitylation. PTEN mono-ubiquitination by the E3 ubiquitin- protein ligase NEDD4 controls 
its nuclear entry (Wang, Trotman et al. 2007). The promyelocytic leukemia protein-herpes 
virus-associated ubiquitin-specific protease (HAUSP) network controls PTEN 
deubiquitination and PTEN nuclear exclusion (Song, Carracedo et al. 2011). Nuclear PTEN 
can induce G0- G1 cell cycle arrest by reducing the level of cyclin D1, and inhibit tumor 
growth by regulating cellular senescence through anaphase promoting complex 
(APC)-CDH1-mediated protein degradation (Waite and Eng 2002; Leslie and Downes 2004).  
A study showed that PTEN can physically associate with centromeres to maintain 
centromeric stability. It is also shown that PTEN is involved in DNA-damage responses 
through upregulation of the transcription of Rad51, a key component of the homologous 
recombination system, which repairs DNA double-strand breaks (DSBs) (Leslie, Batty et al. 
2008; Poliseno, Salmena et al. 2010). This guardian role of PTEN in maintaining 
chromosome structure and function seems to be independent of its lipid phosphatase activity 
(Shen, Balajee et al. 2007; Kim, Xu et al. 2011). Also, nuclear PTEN has a longer half-life and 
is more stable than its cytoplasmic counterpart; therefore the former possibly plays a greater 
role in suppressing tumor formation. 
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1.3.2.4.3 PTEN in melanoma 
As a tumor suppressor, PTEN inhibits melanoma cell growth (Weng, Smith et al. 1999) by 
increasing susceptibility of cells to apoptosis (Lu, Lin et al. 1999). Ectopically expressed 
PTEN protein can inhibit invasion and induce apoptosis in melanoma cells (Stewart, 
Mhashilkar et al. 2002; Stahl, Cheung et al. 2003). PTEN loss and BRAFV600E have been 
shown to cooperate in promoting metastatic melanoma development (Dankort, Curley et al. 
2009). 
Cutaneous melanomas are characterized with a significant frequency of PTEN mutations. 
Mutations/deletions in the PTEN gene were found in 5-15% in primary melanomas and 
metastases, while the frequency of PTEN mutations increases up to 30-40% in melanoma 
cell lines (Tsao, Zhang et al. 1998; Yin and Shen 2008). Chromosome 10 deletion, 
endogenous microRNAs and promoter methylation are mainly responsible for decreased 
PTEN expression in melanoma patient tumor material (Mertens, Johansson et al. 1997; Wu, 
Goel et al. 2003; Mirmohammadsadegh, Marini et al. 2006). Moreover, intragenic 
polymorphisms in introns have been reported to regulate PTEN expression in melanomas 
(Tsao, Zhang et al. 1998; Yin and Shen 2008). Amino acid altering mutations (P95S, F154L, 
L325F) induced by Ultraviolet radiation has been shown to impair PTEN function, which 
promotes the development of early melanomas in xeroderma pigmentosum (Wang, 
Digiovanna et al. 2009).  
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Figure 3: Cytoplasmic and nuclear PTEN functions. PTEN regulates a wide spectrum of biological functions, 
at least in part determined by its subcellular localization. (A) In the cytoplasm dephosphorylation of PIP3 to PIP2 
by PTEN reverses the action of PI3K and hampers all downstream functions controlled by the AKT/mTOR axis, 
such as cycle progression, induction of cell death, transcription, translation, stimulation of angiogenesis, and 
stem cell self-renewal. In addition, PTEN affects cell migration by modulating complex pathways through its 
protein phosphatase activity directed against FAK and SHC. (B) In the nucleus, PTEN can maintain genomic 
integrity, repair DNA DSBs, control homologous recombination, and promote ubiquitin-dependent degradation 
of oncoproteins such as Polo-Like Kinase 1 (PLK1) and Aurora Kinase (AURK). In addition, PTEN modulates 
ERK phosphorylation and cyclin D1 levels to control cell-cycle progression and binds to histone H1 to regulate 
chromatin remodeling (Milella, Falcone et al. 2015).  
1.3.2.5 The insulin-like growth factor system 
The insulin-like growth factor 1 (IGF-1) pathway plays relevant roles in regulating cellular 
proliferation and apoptosis regarding nourishment. Additionally it also regulates energy 
metabolism, body size, longevity and various organ-specific functions (Jones and Clemmons 
1995; Nakae, Kido et al. 2001; Baserga, Peruzzi et al. 2003). The ability of the IGF pathway 
to control rates of cell renewal has led to interest in the relevance of this regulatory system to 
both ageing and neoplasia (Holly 1998; Burroughs, Dunn et al. 1999). It has been shown that 
proliferation and survival of cells propagated in tissue culture can be increased by IGF-1 
stimulation (Jones and Clemmons 1995). Several model systems have confirmed that the 
activation of insulin-like growth factor 1 receptor (IGF-1R) stimulates proliferation and 
promotes metastasis of cancer cells, either in relation to higher levels of circulating IGF-1 in 
the host or to autocrine production of ligands by neoplastic cells (Khandwala, McCutcheon et 
al. 2000). 
The IGF system consists of multiple receptors and ligands. There are three ligands (IGF-1, 
IGF-2 and insulin), four receptors and at least six high-affinity binding proteins and binding 
protein proteases. 
1.3.2.5.1 Ligand and binding protein 
IGF-1 and -2 share 60% homology with proinsulin (LeRoith and Roberts 2003). IGFs and 
insulin bind to their cognate receptor with high affinity and inversely to the noncognate 
receptor with lower affinity. Unlike to insulin, IGFs can be synthesized widely by many cell 
types and are secreted immediately rather than stored intracellularly, while circulating IGF-1 
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is principally produced in the liver regarding growth hormones (D'Ercole, Stiles et al. 1984). 
In the circulation, the ligands are mostly bound to a family of high affinity binding proteins, the 
IGF binding proteins (IGFBPs). They are produced by the liver and range in size from 22 to 31 
kDa. More than 95% of circulating IGF-1 is complexed with IGFBP-3 and the acid labile 
subunit (ALS) (Jones and Clemmons 1995). Although the function of IGFBP varies in relation 
to different cell types, they principally protect IGFs from degradation by proteases and also 
inhibit their interactions with the IGF-1R. It has been shown that IGFBP-1, IGFBP-3 and 
IGFBP-5 have function in ligand independent manner. Among them IGFBP-3 has been 
shown to promote IGF-independent apoptosis and to interact with the retinoid X receptor in 
the nucleus to influence gene transcription (Liu, Lee et al. 2000; Franklin, Ferry et al. 2003). 
Various protease enzymes including prostate-specific antigen (PSA) serve to favor ligand 
binding to the IGF-1R by cleaving IGFBPs (Rajaram, Baylink et al. 1997; Maile and Holly 
1999).  
1.3.2.5.2 Receptor 
The IGF receptor family consists of IGF-1R, the type 2 IGF receptor (IGF-2R) and the insulin 
receptor (IR). The IGF-1R is a tyrosine kinase receptor and is activated by IGF-1, IGF-2 and 
by insulin at supraphysiological concentrations. In humans, the IGF1R gene is located at the 
distal end of chromosome 15, and codes a single polypeptide 1367 amino acid long. After 
removal of the 30 amino acid signal peptide, an endopeptidase cleaves the remaining 1337 
amino acids at the Arg-Lys-Arg-Arg site between residues 707 and 710. This proteolytic 
digestion releases the α- and ß-subunits (Ullrich, Gray et al. 1986). These subunits are 
connected by means of disulfide bonds to give rise to the mature tetrameric receptor: two 
α-subunits is entirely extracellular and responsible for specific ligand binding whereas the two 
ß-subunits span the plasma membrane and encompass an intracellular domain, which 
serves to the initiation of signal transduction cascades (Ward and Garrett 2004).  
The IGF-2R gene encodes for a monomeric transmembrane protein lacking a tyrosine kinase 
domain and has no capability to transduce signaling. It acts as a negative regulator of IGF 
activity though endocytosis and degradation of IGF-2 (Nolan, Kyle et al. 1990). The IGF-2R 
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acts as the mannose-6-phosphate (M6P) receptor to bind lysosomal enzymes and other 
M6P-containing proteins for transfer to the lysosome (Kornfeld 1992; Hille-Rehfeld 1995). 
There are two isoforms of IR generated by alternative splicing of exon 11. IR-A is more highly 
expressed in fetal tissue (Frasca, Pandini et al. 1999). IR-A and IR-B have similar affinities for 
insulin, but IR-A exhibits higher affinity for IGF-2 than IR-B (Yamaguchi, Flier et al. 1993).  
The IGF-1R is closely related to IR. They have a similar tetrameric structure, which is 
composed of two polypeptide chains, each with an extracellular α-subunit and β-subunit. At 
the amino acid level the IGF-1R is 70% homologous to the IR, especially with 84% similarity 
in the tyrosine kinase domain but in C-terminus only 44%, which indicates that there is 
difference in signaling and function for both. (Ullrich, Gray et al. 1986). 
Also, there is hybrid IGF-1R/IR assembled with one αβ chain of IGF-1R and one of IR in cells 
(Frasca, Pandini et al. 1999; Pandini, Vigneri et al. 1999). The IGF-1R/IR-B hybrids exhibit 
affinity to IGF-1 as same as IGF-1R while IGF-1R/IR-A hybrid receptors bind to IGF2 with 
high affinity. Thus, preclinical data have shown that IR plays an important role for regulation 
of IGF action, either as a hybrid or homo IR-A receptor (Morrione, Valentinis et al. 1997; Kalli, 
Falowo et al. 2002). It was considered that the IGF-1R controls mitogenesis, while the IR 
functions in metabolism and glucose homeostasis. However, studies over the past several 
years have revealed that they play distinct and overlapping roles. IR can also function in 
several aspects of breast cancer biology, either as a hybrid or homoreceptor (Sciacca, Mineo 
et al. 2002). 
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Figure 4 Schematic representation of the IGF-1R. IGF-1R is a heterotetrameric molecule, composed of two 
identical polypeptide chains, each with a α- and β-chains linked by disulfide bonds. The α-chains are 
extracellular and responsible for specifically binding of the growth factors, while the β-chains contain a short 
extracellular region, a transmembrane region, an intracellular tyrosine kinase domain, and a C-terminal tail. Key 
residues of the IGF-1R are shown on left side. The amino acid numbers in this figure are those of the human 
receptor after removal of the 30 amino acid signal peptide (Baserga 2005). 
1.3.2.5.3 IGF-1R signaling  
Binding of IGFs to IGF-1R results in a conformational change in the receptor, which leads to 
an auto-phosphorylation of tyrosines 1131, 1135 and 1136 in the kinase domain, 
juxtamembrane tyrosines and C-terminal serines (Kato, Faria et al. 1994; Parvaresch, 
Yesilkaya et al. 2002). These phosphorylation events recruits signaling intermediates 
including insulin-receptor substrate (IRS)- 1 and -2, Shc, Grb10, and 14-3-3e (Myers, 
Grammer et al. 1994; White and Kahn 1994; Craparo, O'Neill et al. 1995; Craparo, Freund et 
al. 1997), and in turn results in activation of distinct signaling pathways (Ricketts, Rose et al. 
1996; Nguyen, Wang et al. 2000). The first detailed study of IGF-1R regulated pathway 
focused on the PI3K/AKT pathway. The phosphorylated IGF-1R can recruit PI3K via SH2 
domains of the adaptor protein p85 through phosphorylated IRS to the cell membrane, where 
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PI3K is activated and leads to synthesis of membrane-associated PIP3. This leads to 
activation of PDKs, and in turn a spectrum of downstream protein kinases, including AKT, 
p70RSK and protein kinase C (PKC) are phosphorylated and activated (Vanhaesebroeck 
and Alessi 2000; Manning and Cantley 2007). Through these effectors IGF-1R controls a 
wide range of effects, including mitogenesis, proliferation, cell cycle control and inhibition of 
apoptosis (Vanhaesebroeck and Alessi 2000). The second major principal signaling pathway 
is MAPK pathway. Recruitment of the SOS to IRS-1 or Shc, via the SH2 domain of the Grb2 
adaptor protein leads to activation of the small G protein RAS, which in turn activates the 
protein serine kinase Raf and the MAPK pathway (Davis 1995). This pathway mediates cell 
proliferation and differentiation. In addition to these two principal pathways mediated via 
tyrosine-phosphorylated IRS and/or Shc, a spectrum of proteins can interact directly with the 
receptors and act independently or in synergy with IRS and Shc. For example, the IGF-1R 
can interact directly with14-3-3 proteins, causing the translocation of c-Raf to the 
mitochondria and by this protects cells from apoptosis (Peruzzi, Prisco et al. 1999). Moreover, 
phospholipase C and PKC, the signal transducers and activators of transcription (STATs), 
and their negative regulators the suppressors of cytokine signaling (SOCS) can also be 
activated directly by IGF-1R (Chen, Sadowski et al. 1997; Dey, Spence et al. 1998; Zong, 
Zeng et al. 1998). Unlike the widespread expression of the IGF-1R, IR expression is 
restricted to the liver, adipose tissue and muscle. Activation of IR by binding Insulin leads to 
glucose uptake and inhibition of gluconeogenesis in the liver (Olefsky 1990; White and Kahn 
1994). Although IGF-1R and IR signaling have a few common and overlapped functions, they 
differ in many aspects, including the different patterns of receptor expression, kinetics of 
ligand binding, recruitment of signaling intermediates and effects on gene expression (De 
Meyts, Christoffersen et al. 1995; Siddle, Urso et al. 2001).  
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Figure 5 Signaling pathways of the IGF-1R. Schematic diagram of the three main pathways originating from 
the IGF-1R. Binding of IGF-1/2 to IGF-1R leads to autophosphorylation of its tyrosine kinase domain and 
subsequently various cytoplasmic mediators are activated. Particularly important pathways are the 
RAS-Raf-MEK-ERK1/2 and the PDK-AKT-mTOR signaling systems. Also, direct interaction of IGF-1R with 
14-3-3 proteins causes the translocation of c-Raf to the mitochondria. Though these mediators IGF-1R controls 
a wide range of effects, including mitogenesis, proliferation, cell cycle control and inhibition of apoptosis 
(Baserga 2005). 
1.3.2.5.4 IGF-1R in melanoma 
IGF-1R is overexpressed in melanoma and is correlated with melanoma progression 
(Kanter-Lewensohn, Girnita et al. 2000). Previous studies have demonstrated that IGF-1 
stimulation promotes proliferation of early-stage melanoma cells, but not metastatic 
melanoma cells (Satyamoorthy, Li et al. 2001). A more recent study showed that IGF-1 
inhibits tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis 
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by inducing expression of BCL2, BCL-xl and surviving (Hilmi, Larribere et al. 2008). 
Downregulation of IGF-1R expression or activity causes growth arrest and apoptosis 
(Kanter-Lewensohn, Dricu et al. 1998; Kanter-Lewensohn, Girnita et al. 2000; Maloney, 
McLaughlin et al. 2003). Also, several studies have shown that human melanoma cells 
expressing BRAFV600E are susceptible to IGF-1R targeting (Maloney, McLaughlin et al. 2003; 
Yeh, Bohula et al. 2006; Macaulay, Middleton et al. 2013). Recently, the importance of 
IGF-1R expression and activity was stressed again in therapy-resistance of malignant 
melanoma against the BRAFV600E inhibitor PLX4032 (Villanueva, Vultur et al. 2010). 
Interestingly, the persistent IGF-1R activity in melanoma cells resistant to the BRAF inhibitor 
was not mediated by an autocrine IGF-1 mediated signalling (Villanueva, Vultur et al. 2010). 
In line with this, a recent study showed that fibroblast-derived IGF-1 could not mediate 
resistance towards BRAF inhibition (Straussman, Morikawa et al. 2012). This suggests that 
the enhanced expression and activity of IGF-1R signalling in melanoma cells is regulated by 
melanoma cell intrinsic regulatory mechanisms.  
1.4 Aim of the project 
Among RTKs, the IGF-1R is one of the most important players in cancer development. In 
melanoma, the IGF-1R is overexpressed compared with benign naevi (Kanter-Lewensohn, 
Girnita et al. 2000). IGF-1R antisense oligonucleotides have been shown to inhibit melanoma 
cell survival in vitro and the growth of FO-1 melanoma xenografts in nude mice (Resnicoff, 
Coppola et al. 1994). Knockdown of IGF-1R is capable of inducing significant survival 
inhibition and enhancement of apoptosis, regardless of BRAF mutation status (Maloney, 
McLaughlin et al. 2003; Yeh, Bohula et al. 2006; Macaulay, Middleton et al. 2013). The 
importance of IGF-1R expression and activity was stressed again in therapy-resistance of 
malignant melanoma against the BRAFV600E inhibitor PLX4032 (Villanueva, Vultur et al. 
2010). These findings suggest that the IGF-1R is an attractive target for melanoma treatment. 
However, in clinical settings, no clear mechanism of aberrant IGF-1R could be recognized. 
The large increases in receptor number are rarely associated with gene amplification. 
Therefore, a deeper understanding of the molecular mechanisms regulating IGF-1R 
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expression and activity in melanoma cells is indispensable. 
In this study we analyzed the regulatory mechanisms involved in enhancing IGF-1R 
expression and activity in melanoma cells and the impact on therapy resistance of melanoma 
cells. We focused on the impact of the MAPK- and PI3K/AKT pathways on IGF-1R 
expression and activity.  
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2 Materials and Methods  
2.1 Materials 
2.1.1 Cell lines 
Cell lines Obtained from Described in Mutation  
451Lu Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
Andalib, Lawry et al. 
1997 
BRAFV600E 
NRAS WT 
PTEN nd 
SKMEL19 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
Carey, Takahashi et 
al. 1976 
BRAFV600E 
NRAS WT 
PTEN WT 
1205Lu Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
Andalib, Lawry et al. 
1997 
BRAFV600E 
NRAS WT 
PTEN Mu/ Hem Del 
WM3734 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
The Wistar Institute BRAFV600E 
NRAS WT 
PTEN Hom Del 
MDAMB435 ATCC Rae, Creighton et al. 
2007 
BRAFV600E 
NRAS WT 
PTEN WT 
Malme-3M ATCC Fogh, Wright et al. 
1977 
BRAFV600E 
NRAS WT 
PTEN WT 
M14 ATCC Paraiso, Xiang et al. 
2011 
BRAFV600E 
NRAS WT 
PTEN WT 
WM35 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
Paraiso, Xiang et al. 
2011 
BRAF WT 
NRASQ61R 
PTEN WT 
WM115 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
The Wistar Institute BRAF WT 
NRAS WT 
PTEN Hem Del 
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WM793 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
Paraiso, Xiang et al. 
2011 
BRAFV600E 
NRAS WT 
PTEN Mu/Hem Del 
WM266 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
The Wistar Institute BRAFV600E 
NRAS WT 
PTEN Hem Del 
IGR39 C. Garbe 
(Department of 
Dermatology, 
University of 
Tübingen, Germany 
Aubert, Chirieceanu 
et al. 1976 
BRAFV600E 
NRAS WT 
PTEN Hem Del 
A375 ATCC Giard, Aaronson et 
al. 1973 
BRAFV600E 
NRAS WT 
PTEN WT 
SKMel147  Wang, Lee et al. 
2012 
BRAF WT 
NRASQ61R 
PTEN nd 
SKMel30  Carey et al., 1976 BRAFD287H 
NRASQ61K 
PTEN WT 
MV3 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
van Muijen, Jansen 
et al. 1991 
BRAF WT 
NRASQ61R 
PTEN WT 
M1617 Meenhard Herlyn, 
Wistar Institut, 
Philadelphia, USA 
Villanueva, Vultur et 
al. 2010 
BRAFV600E 
NRAS  nd 
PTEN WT 
* WT: wild-type; Mu: mutated; Hem Del: hemizygous deletion; nd: no data available 
Cell line Cell type Prepared from 
FF (foreskin fibroblasts) Primary fibroblasts Foreskin  
Melanocytes Primary melanocytes Foreskin 
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2.1.2 Antibodies 
Antibody Source Catalog- 
number 
Dilution Distributor 
ß-Actin  Rabbit #4967 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
AKT3 Rabbit #3788 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
AKT Rabbit #4685 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
phospho-AKT 
(Ser473) 
Rabbit #4060 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
ERK Rabbit #9102 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
phospho-ERK 
(Thr202/Thr204) 
Rabbit #9101 
1:1000 
(WB) 
1:100(FC) 
Cell Signaling (NEB),  
Frankfurt a. M. 
pIGF-1R Rabbit #3918 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
IGF-1Rß Rabbit #3027 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
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IGF-1Rß Rabbit sc713 IHC 
Santa Cruz Biotechnology, 
Heidelberg 
IRS1  Rabbit #3407 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
IRS2 Rabbit #3089 
1:1000 
(WB) 
Cell Signaling (NEB),  
Frankfurt a. M. 
B-Raf Mouse sc5284 1:500(WB) 
Santa Cruz Biotechnology, 
Heidelberg 
PTEN Rabbit # 9559 
1:1000 
(WB) 
(IHC) 
Cell Signaling (NEB),  
Frankfurt a. M. 
IgG HRP-linked anti-Rabbit #7074 1:2500 
Cell Signaling (NEB),  
Frankfurt a. M. 
IgG HRP-linked anti-Mouse #7076 1:2500 
Cell Signaling (NEB),  
Frankfurt a. M. 
IGF-1R α Mouse 555999 (FC) 
BD, Pharmingen, 
Heidelberg 
IgG1 Mouse 555749 (FC) 
BD, Pharmingen, 
Heidelberg 
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APC conjugated 
anti-mouse IgG1 
Rabbit 560089 1:100(FC) 
BD, Pharmingen, 
Heidelberg 
APC conjugated 
anti-rabbit IgG1 
Mouse #5366 1:100(FC) 
Cell Signaling (NEB),  
Frankfurt a. M. 
C3 conjugated anti 
rabbit igG1 
Donkey  (IHC) Dianova  GmbH,Hamburg 
C5 conjugated anti 
mouse igG1 
Donkey  (IHC) Dianova  GmbH,Hamburg 
* WB: Western Blot; IHC: Immunohistochemistry; FC: Flow Cytometry 
2.1.3 Materials and Kits 
Material Distributor 
      e  ranes Roche, Mannheim 
Biocoat:  Collagen I Coated Cultureware BD Biosciences, Heidelberg 
Nucleospin RNAII Kit Macherey&Nagel, Düren 
X-ray Film Kodak X-OMAT 
Eastman Kodak Company, 
Rochester 
Superscript II Reverse Transkriptase Invitrogen, Darmstadt 
SYBR Green Real-time PCR Mix 
BioRad, München; Roche, 
Mannheim 
Lipofectamin 2000  Transfection Reagent Invitrogen, Darmstadt 
Lipofectamin RNAimax Transfection Reagent Invitrogen, Darmstadt 
Whatman 3mm-Paper Roth, Karlsruhe 
QIAquick DNA Gel Extraction Kit Qiagen, Hilden 
Amersham ECL Prime Wester Blotting Detection 
Reagent 
GE healthcare life science, 
Schwerte 
Pierce ECL Western Blotting Substrate Thermo Fisher Scientific, Bonn 
Competent Ecoli 
Clontech,Saint-Germain-en-Laye, 
France 
Protein Assay Kits Bio-Rad,  München 
2.1.4 Chemicals 
Substance Distributor 
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Fetal Calf Serum (FBS)  Biochem Berlin 
Penicillin/ Streptomycin Gibco, Schwerte 
Puromycin 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
Gentamycin Gibco, Schwerte 
OPTIMEM Medium Gibco, Schwerte 
DMEM (dulbecco's modified eagle's medium) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
RPMI  Gibco, Schwerte 
Polybrene 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
4-Methylumbelliferyl Heptanoate (MUH) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
Phosphate Buffered Saline (PBS) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
Propidium Iodide (PI) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
5x Passive Lysis Buffer  Promega, Mannheim 
Agar Noble Difco, Heidelberg 
PLX4032 
LC Laboratories, 
Woburn,USA 
AZD 6244 Absource Diagnostics 
GmbH,  München 
Cell Lysis Buffer 
Cell Signaling (NEB),  
Frankfurt a. M. 
Bovine Serum Albumin (BSA) Roth, Karlsruhe 
Polyacrylamide Roth, Karlsruhe 
No Fat Milk 
Cell Signaling (NEB),  
Frankfurt a. M. 
Ampicillin Sigma Aldrich Chemie 
GmbH, Taufkirchen 
Gelred Nucleic Acid Gel Stain Biotium, Köln 
Para-formaldehyd (PFA) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
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Picropodophyllin (PPP) Calbiochem, Darmstadt 
PI-103 Calbiochem, Darmstadt 
Ipatasertib (AKTi) Selleck chemicals Müchen 
BKM Selleck chemicals Müchen 
GDC0941 Selleck chemicals Müchen 
Recombinant Human IGF-1 
R&D Systems GmbH, 
Wiesbaden-Nordenstadt  
Doxycyclin 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
BES Calbiochem, Darmstadt 
RNase Fermentas, St. Leon-Rot 
Ethylene Diamine Tetraacetic Acid(EDTA) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
YO-PRO-1  Invitrogen, Darmstadt 
Cycloheximide (CHX) 
Sigma Aldrich Chemie 
GmbH, Taufkirchen 
HMB45 DAKO,  
G418  
Sigma Aldrich Chemie 
GmbH, Taufkirchen and 
DAKO 
2.1.5 Devices 
Device Type/Company 
Vacuum Pump System IV-500 Vacuset Multi-Tip Kit (Inotech) 
Blot Equipment 
Trans-Blot SD Semi-Dry Transfer Cell 
(Bio-Rad) 
CO2 Incubator 
HERAcell 240 CO2 Incubator  
BBD 6220 ; T6 function line (Heraeus) 
Electrophoresis Chamber Mini-PROTEAN (Bio-Rad) 
Heat Sealing Machine Folio FS 3602 (Severin)  
Heating Block Dry-Block DB-2D (Techne)  
Camera  E-300 (Olympus) 
Refrigerator FKS 500 (Liebherr); HFU 586 (Heraeus) 
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Magnetic Stirrer RCT basic (IKA Labortechnik) 
Microscope CK 40 (Olympus) ; IX50 (Olympus) 
Microwave MW600 (Bosch) 
Power Supply 
Power Supply EPS 200 (Pharmacia 
Biotech); Power Pac 300 (BioRad)  
pH-meter  Knick pH-Meter 761 (Calimatic) 
Spectrophotometer Smartspec plus (Biorad) 
Microplate reader TriStar LB 941 (Berthold Technologies) 
Realtime PCR System  
iCycler (Biorad); LC480 (Kalli, Falowo et 
al.) 
Roll Mixer RM5 (Fröbel Labortechnik) 
X-ray Cassette Röntgenkassette (Dr. Goos-Suprema 
Incubator Shaker HT (Infors)  
Shaker HS250 (IKA Labortechnik) 
Safety Cabinets 
Herasafe HS18 (Heraeus); MRF-B 
(Steag) 
Thermocycler PTC200 (MJ Research) 
Ultra Centrifuge 10SW Rotor (Sorvall)  
Vacuum Pump N180.3 (KNF Neuberger) 
Vortexer  Vortex-Genie 2 (Scientific Industries) 
Scale LC 821 (Sartorius); Kern 770 (Kern) 
Water Bath 1083 (Gesellschaft für Labortechnik) 
Centrifuge 
 
 
 
 
 
Biofuge pico (Heraeus) 
Biofuge 13 (Heraeus) 
Megafuge 1.0R (Heraeus) 
Varifuge 3.0R (Heraeus) 
Biofuge fresco (Heraeus) 
ZK 401 (Hermle) 
Bacterium Incubator HT (Infors) 
Flow Cytometer BD LSRII (BD Biosciences) 
Gel Documentation 
EpiChem3 Darkroom (UVP BioImaging 
Systems) 
Confocal  Microscope  TCS SP (Leica) 
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Fluorescence Microscope AXIO IMAGER.A2 (Zeiss) 
2.1.6 Software 
Programm Company 
Acrobat Reader Adobe 
Word Microsoft 
Excel Microsoft 
Powerpoint Microsoft 
Photoshop Adobe 
Graphpad Prism Version 5.01 GraphPad 
ICycler iQ Bio-Rad 
LC480 Roche 
Microwin 2000 4.41 Microtek 
Confocal Software 2.61 Leica 
Scion Image Scion Corporation 
BD FACS DIVA BD Biosciences 
LEICA TCSSP Leica 
FCS EXPRESS De Novo software 
2.1.7 Oligonucleotides 
Gene Sequence 
siControl Sense      5’-acaacauucauauagcugccccc-3’ 
Anti sense  5’-gggggcagcuauaugaauguugu-3’ 
siAKT3 Sense      5’-gcucauuacuaggauauaatt-3’ 
Anti sense  5’-uuauauccuaugaauga cca-3’ 
siBRAF Sense      5’-ggagguguggaauaucaaatt-3’ 
Anti sense  5’-uuugauauuccacaccucctc-3’ 
siIGF-1R 
 
Sense      5’-gcaugguagccgaagauuutt-3’ 
Anti sense   5’-aaaucuucggcuaccaugcaa-3’ 
 
Gene PCR primer Sequence 
GAPDH Forward 5’-CTGACTTCAACAGCGACACC-3’ 
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Reverse 5’-TAGCCAAATTCGTTGTCATACC-3’ 
IGF-1R Forward 5’-GCCGACGAGTGGAGAAATC-3’ 
Reverse 5’-GAGGTAGCCCTCGATCACC-3’ 
18S rRNA Forward 5’-CGGCTACCACATCCAAGGAA-3’ 
Reverse 5’-GCTGGAATTACCGCGGCT-3’ 
 
2.1.8 Plasmids 
2.1.8.1 pMD2.G 
Envelope plasmid used for lentivirus production. Mammalian expression of Vesicular 
Stomatitis Indiana Virus protein G (VSV-G) driven by the cytomegalovirus (CMV) promoter. It 
contains ampicillin resistance in bacteria. pMD2.G was a gift from Didier Trono at the Swiss 
Federal Institute of Technology Lausanne (Addgene plasmid # 12259). 
 
Figure 6:  pMD2.G vector map generated by Addgene from full sequence supplied by depositor. 
2.1.8.2 psPAX2   
The plasmid is a second-generation packaging plasmid used to produce human 
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immunodeficiency virus 1 (HIV-1) derived lentivectors, which encodes for the Gag/Pro/Pol 
genes derived from HIV-1. The promoter is the chicken beta actin promoter and the 
polyadenylation signal is the rabbit beta globin polyA. Resistance to Ampicillin. psPAX2 
was a gift from Didier Trono at the Swiss Federal Institute of Technology Lausanne 
(Addgene plasmid # 12260). 
 
 
Figure 7: psPAX2 vector map generated by Addgene from full sequence supplied by depositor. 
2.1.8.3 pLVX-Tet-On Advanced 
The pLVX-Tet-On Advanced vector constitutively expresses the tetracycline-controlled 
transactivator, rtTA-Advanced, which is under the control of CMV promoter. In addition to 
lentiviral elements, this vector contains a geneticin resistance gene to be used for the 
selection of stable transductants. The vector also contains a pUC origin of replication and an 
E. coli ampicillin resistance gene (Ampr) for propagation and selection in bacteria. 
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Figure 8: pLVX-Tet-On Advanced vector map generated by Clontech Laboratories, Inc. 
(Protocol No.PT3990-5). 
2.1.8.4 PLVX-tight-Puro 
pLVX-Tight-Puro is a tetracycline (Tet)-inducible, lentiviral expression vector. It is designed to 
express a gene of interest under the control of PTight, a modified Tet-responsive promoter, 
which is composed of a modified minimal CMV promoter, and seven direct repeats of a 36 bp 
regulatory sequence containing the 19 bp Tet operator sequence (tetO). This vector is 
designed to be used with Lenti-X Tet-On Advanced. In addition to lentiviral elements, 
pLVX-Tight-Puro contains a puromycin resistance gene (Puror) under the control of the 
murine phosphoglycerate kinase (PGK) promoter (PPGK) for the selection of stable 
transductants. The vector also contains a pUC origin of replication and an Ampr for 
propagation and selection in bacteria. Wild-type PTEN or mutants, wild-type BRAF or 
BRAFV600E and IGF-1R were cloned into multiple cloning sites  etween 5’cloning site EcoRI 
and 3’ cloning site BamHI. 
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Figure 9: PLVX-tight-Puro vector map generated by Clontech Laboratories, Inc. (Protocol No.PT3996-5). 
2.1.8.5 AKT3 expression plasmid 
pcDNA3 are 5.4 kb vectors and designed for high-level stable and transient expression in 
mammalian hosts.  A full length complementary DNA (cDNA) encoding the human AKT3 was 
subcloned into the mammalian expression vector at the multiple cloning sites between 
5’cloning site HindIII and 3’ cloning site EcoRI. A c-Src myristoylation sequence and a 
hemagglutinin (HA)-epitope are fused in frame to the N terminus of the AKT3 coding 
sequence generating MYR-HA AKT3 which is constitutively expressed under the control of 
CMV promoter. The myristoylation tethers AKT3 to the inner surface of the plasma 
membrane so that the AKT3 can be constitutively activated. The pcDNA3 Myr HA Akt3 was a 
gift from William Sellers at Loyola University Chicago (Addgene plasmid # 9017). 
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Figure 10:   pcDNA3 Myr HA Akt3 vector map created using PlasMapper according plasmid data. 
2.1.8.6 pGIPZ lentiviral vector  
GI Z Lentiviral™ Short hairpin RNA (shRNA) was developed  y Ther o Scientific™ in 
collaboration with Dr. Greg Hannon of Cold Spring Harbor Laboratory and Dr. Steve Elledge 
of Harvard Medical School. shRNA constructs are expressed as human microRNA-30 
(miR-30) primary transcripts. A drosha processing site is added to the hairpin construct .The 
hairpin stem consists of 22 nucleotides (nts) of double-stranded (ds) RNA and a 19 nts loop 
from human miR-30. Each shRNA construct has been bioinformatically verified to match 
NCBI sequence data. In addition the vector contains a puromycin resistance gene and 
TurboGFP gene under the control of the CMV promoter for the selection of stable 
transductants and the visual marking. Lentiviral shRNA construct against PTEN was gift from 
Sebastian Haferkamp (Regensburg, Germany). 
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 Figure 11: pGIPZ lentiviral vector map generated by GE Healthcare Dharmacon Inc. 
(http://dharmacon.gelifesciences.com/uploadedFiles/Resources/gipz-lentiviral-shRNA-manual.pdf) 
2.2 Cell culture 
2.2.1 Thawing, passaging and cryopreservation of mammalian cells  
Most mammalian cells can be stored in liquid nitrogen for many years. The viability of the 
cells depends on their ability to cope with the variety of stresses imposed on them during the 
freezing and thawing procedures.  
Cells were taken out of nitrogen storage and thawed rapidly by swirling in the 37°C water bath. 
5 ml culture medium is added to cells. After centrifugation, cells are resuspended in the 
culture medium, pipetted into a T75 culture flask and placed in a CO2 incubator for growth of 
new culture.  
All used human melanoma cell lines were grown in RPMI 1640 medium with 10% FBS, 1% 
penicillin and streptomycin. For passaging, after washing with PBS, 2 ml trypsin is added. 
Cells are placed back to the incubator until all of cells were detached from the culture flask. 5 
ml culture medium was added to neutralize trypsin. After centrifugation at 1200 revolutions 
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per minute (rpm) for 3 minutes (Slominski, Tobin et al.) (Megafuge 1.0R), appropriate cell 
numbers are resuspended in growth medium.  
For cryopreservation, cells were trypsinized and pelleted by spinning the cells as gently as 
possible (1200 rpm, 3 minutes; Megafuge 1.0R), then 1 x 106 cells/ml were resuspended in 
freezing medium (10% DMSO, 20% FCS, 70% growth medium like RPMI or DMEM). Vials 
are placed upright in a styrofoam box and covered well, then put in a -20°C refrigerator for 24 
hours.  ials were stored upright on ice until placed in a “ r.  rosty” freezing box containing 
isopropanol at 4°C. This freezing box is placed at -80°C over night for slow freezing of the 
cells. Finally, vials are putted in a liquid nitrogen container. 
2.2.2 Isolation of melanocytes and fibroblasts from human foreskin 
Melanocytes and fibroblasts were isolated from human foreskin obtained from circumcision. 
First subcutaneous fat and blood vessels were removed and the tissue was cut into pieces 
approximately 5 mm  5 mm  5 mm in size. The explants were placed with epidermal side 
down in 2 ml solution B for about 20 hours at 4 °C for enzymatic digestion. To mechanically 
separate epidermis from dermis the explants were placed into a petri dish containing 1 ml 
solution A and scratched repeatedly with a scalpel blade. The isolated epidermal fragments 
were transferred into a 15 ml tube with 5 ml solution A and melanocytes were dissolved from 
epidermis by around 60 times resuspending by pipette. After centrifugation at 1200 rpm for 4 
minutes (Megafuge 1.0R), the pellets were resuspended in 5 ml melanocyte medium and 
transferred into a T25 culture flask to grow in a CO2 incubator at 37°C. It could be that 
fibroblasts and keratinocytes were isolated as well. Due to their higher sensitivity to trypsin 
melanocytes are able to be separated from the other cells.  
Fibroblasts are obtained from the dermis. The dermal explants are placed into one well of a 6 
well plate and covered with DMEM medium until fibroblasts grow out. Reaching appropriate 
confluence fibroblasts were harvested and cultured further. 
Table 1:  Medium for cell isolation from human foreskin 
Transport medium Solution B Solution A 
volume substrate concentration substrate concentration substrate 
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500 ml HBSS 30 mM Hepes 30 mM Hepes 
 gentamycin 4 mM Glucose 10 mM Glucose 
5 ml penicillin 3 mM KCl 3 mM KCl 
 streptamycin 130 mM NaCl 130 mM NaCl 
 amphotericin 1 mM Na2HPO4 1 mM Na2HPO4 
  0,25% Trypsin  H2O 
   H2O   
All of the cell lines used in our study were authenticated by sequence analysis of defined 
genes. The use and culturing of human skin tissues in this study was approved by the 
medical ethical committee of the University of Tübingen (43/2008B01; 16/2009B02) and was 
performed in accordance with the Declaration of Helsinki Principles. All patients provided 
informed written consent. 
2.2.3 Plasmid and siRNA Transfektion  
In order to deliver plasmids or transfect small interfering RNA (siRNA) into melanoma cells, 
lipofection is done by using Lipofectamin 2000 or Lipofectamin RNAiMAX. Lipofectamine is 
able to form cationic liposomes in an aqueous environment, which entrap negatively charged 
nucleic acid molecules. The nucleic acid containing liposomes with positive charge on their 
surfaces can fuse with the negatively charged plasma membrane of living cells, which allows 
nucleic acid to cross into the cytoplasm and contents to be available to the cell for replication 
or expression. 
2.2.3.1 Plasmid transfection 
An appropriate number of tumor cells are seeded in a cavity of a 6-well plate, so that the cell 
density gets 90-95% confluent on the day of transfection. 10 µl lipofectamin 2000 was diluted 
in 250 µl OPTI-MEM and incubated for 5 minutes, and 4 µg of the plasmid was diluted in 250 
µl OPTI-MEM as well, then both of them were mixed very well and incubated 20-30 minutes 
to form complex of liposomes with plasmid. At the same time the culture medium on cells was 
replaced by an antibiotic free culture medium at a total volume of 2 ml to avoid cell death 
during transfection. The 500 µl of complexes were added slowly to cells. After 4 hours the 
culture medium was exchanged. 
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2.2.3.2 siRNA transefection 
To transfect siRNA to melanoma cells, Lipofectamin RNAiMAX is used, because it has low 
toxicity and high efficiency to deliver siRNA into cells. For siRNA transfection, cells are plated 
in a cavity of 6-well plate to get a 50-70% confluent cell density on the day of transfection. 
siRNA and RNAiMAX are separately diluted in 250 µl OPTI-MEM medium, then mixed 
together very well, and incubated for 20-30 minutes to form complexes. The culture medium 
on cells was replaced by antibiotic free medium. The 500 µl of siRNA/RNAiMAX mixture were 
added to the cells. After 24 hours the culture medium was replaced.  
2.2.4 Gene delivery by Lentivirus infection  
2.2.4.1 Ca3(PO4)2-transfektion 
13x106 293T cells are seeded in T175 culture flask. 3.5 µg of envelope plasmid (pMD2.G), 
6.5 µg of packaging plasmid (psPAX2) and 10 µg of expressing plasmids are added 
individually to 5 ml H2O in a 15 ml tube, then 500 µl of 2M CaCL2 is added and mixed very well 
by pipette. 550 µl of 2x BES-buffered solution (Melero, Hervas-Stubbs et al.) are added to the 
mixture of plasmids in drops while air is blowed to the mixture using an electronic pipette, so 
that fine crystals can continuously form, which contain the transfected plasmids. The mixture 
is incubated for 30 minutes at room temperature (RT), then added to cells in drops. After 4 
hours the culture medium is refreshed. 
2X BBS  
50 mM BES(N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) 
280 mM NaCl 
1.5 mM Na2HPO4 
Adjust to pH 6.95 with 1 N NaOH, RT 
Filter sterilize through a 0.45 µm nitrocellulose filter 
2.2.4.2 Purification of lentivirus  
Lentiviral vectors offer unique versatility and robustness as vehicles for gene delivery. They 
can transduce a wide range of cell types and integrate into the host genome in both dividing 
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and post-mitotic cells, resulting in long-term expression of the transgene both in vitro and in 
vivo. 
Lentiviral vectors were produced by cotransfection of a lentiviral transfer and other plasmids 
for packaging into 293T cells by calcium phosphate transfection method. 2 and 3 days after 
transfection the supernatants were collected in 50 ml tubes, and centrifuged at 2000 rpm for 
10 minutes (Megafuge 1.0R) to pellet any cells/cellular debris. The supernatants were filled 
into conical tubes and centrifuged for 2 hours at 17000 rpm (ZK401) and 4°C. The 
supernatants were discarded without disturbing the pellets. Small translucent viral pellets 
were resuspended in DMEM medium in a total volume of 500 µl. Finally the concentrated viral 
vectors are transferred to a fresh microcentrifuge tube and 20 μl aliquots were prepared, 
which are stored at -80°C.  
2.2.4.3 Infection of tumor cells with lentivirus 
5x105 cells are seeded in a T25 culture flask. At the next day 50 µl of viral vectors were 
incubated with 2 µl of polybrene (4 µg/µl) for 5minutes in a sterile 1.5 ml tube. The target cells 
were brought to room temperature and culture medium was aspirated. 1 ml of fresh culture 
medium were mixed with viral vectors, transferred completely to the cells and incubated 
overnight in a humidified incubator in an atmosphere of 5% CO2. At the second day medium 
containing virus was replaced. After rinsing with PBS, 5 ml of culture medium was added to 
cells for growing for 48 hours. Puromycin with a proper concentration was added to culture 
medium until non-transduced cells are completely killed. 
2.2.5 MUH-Assay 
The fluorimetric method using 4-methylumbelliferylheptanoate (MUH) has been developed 
for detecting cytotoxicity and cell proliferation. The assay is based on the hydrolysis of the 
fluorochrome by intracellular esterases of viable cells resulting in the production of highly 
fluorescent 4-methylumbelliferone that can be measured in a microplate fluorimeter.  
For the assay 1500 cells/well are seeded in 96-well-plate and incubated overnight. The 
inhibitors were added to the cells at the indicated concentrations and incubated for 72 hours 
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at 37°C. After 72 hours the medium on cells was aspirated and the cells were washed with 
PBS twice. Then 100 µl of the prepared MUH solution (100 μg/ml in PBS) is added to each 
well and incubation occurred for 1 hour at 37°C in a CO2 incubator. The production of highly 
fluorescent 4-methylumbelliferone was measured in a microplate fluorimeter (Berthold) with 
Ex355/Em460 nm. 
2.2.6 Apoptosis and cell cycle analysis 
DNA-binding dyes can bind in proportion to the amount of DNA present in the cell. In this way 
the cell phases, in which the amount of DNA contents differ, can be divided according to the 
intensity of the DNA dyes. Due to fragmentation of chromosome during apoptosis the 
population of apoptotic cells has lower DNA content than that in other phases.  
Both floating and attached cells were harvested and fixed in 70% ethanol overnight. Cells 
were stained with PBS containing 50 µg/ml PI and 50 U RNase A. After 30 minutes cells were 
measured by LSRII fluorescence-activated cell sorting (FACS; BD, Heidelberg, Germany). 
The amount of apoptotic cells (sub-G1) was analyzed using the BD FACSDiva software. 
2.2.7 Two and three-dimensional co-culture 
2.2.7.1 Two dimensional co-culture  
96 well plates were coated with 1x103 SKMEL19 or dermal fibroblasts, GFP labeled 
SKMEL19 were seeded onto them and incubated for 24 hours. PLX4032 was added at the 
indicated concentrations and incubated for another 3 days. After PBS washing, 50 µl lysis 
puffer (Promega) was added per well. Plates were frozen at -80°C overnight. After thawing 
and strongly pipetting, 30 µl lysate was added to a black 384 well plate and GFP intensity was 
measured by a fluorescence microplate reader (Berthold) with Ex485/Em535 nm in 
triplicates. 
2.2.7.2 Three dimensional co-culture (spheroids)  
1x103 SKMEL19 or dermal fibroblasts were seeded in 1% agar noble (Difco) coated 96-well 
plates for 24 hours. Then GFP labeled SKMEL19 were added and incubated for 2 days. 10 
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µM PLX4032 was added to the spheroids. Inhibitor was refreshed every 3 days. Cell viability 
was determined by expression of GFP by fluorescent microscope (Axiovert, Zeiss) up to 8 
days. 
2.2.8 Cell surface and intracellular staining 
5x105 cells were seeded in T25 culture flask and incubated overnight. PLX4032 or AZD6244 
was added at indicated concentrations for 24 hours. After PBS washing, cells were detached 
using 0.2% EDTA/PBS. For surface staining, cell pellets were resuspended in 100 µl cold 
PBS with IGF-1R antibody or isotype control (BD, Pharmingen) and incubated on ice for 45 
minutes. After PBS washing, cells were resuspended in PBS with APC conjugated rabbit 
anti-mouse antibody (BD, Pharmingen) and incubated in the dark on ice for 30 minutes. 
For intracellular staining, cell pellets were fixed in 2% PFA for 10 minutes at RT. After 
washing with PBS with 2% FBS, cells were resuspended in PBS with 0.5% Saponin 
containing pERK antibody (Cell Signaling Technology) and 2% FBS for 30 minutes. After 
washing with PBS with 2% FBS, cells were resuspended in PBS with APC conjugated mouse 
anti rabbit antibody (Cell Signaling Technology) and 2% FBS for 30 minutes. The intensity of 
IGF-1R or pERK was measured by LSRII fluorescence-activated cell sorting (FACS; BD, 
Heidelberg, Germany). Overlay was made by using FCS Express (De Novo software). 
2.2.9 IC50 determination 
2x103 cells were seeded per well into 96 well plates. Picropodophyllin (PPP) was added with 
gradient concentrations and incubated for 72 hours. Cell viability was measured by MUH 
assay. We determined the half maximal inhibitory concentration (IC50) of PPP, at which 50% 
of the melanoma cells were killed, using the function of Dose-Response-Inhibition analysis at 
GraphPad Prism version 5.01 (GraphPad Prism Software Inc.). 
2.2.10 Immunofluorescence and immunohistochemical analysis 
4.5% PFA fixed melanoma cells or sections of paraffin-embedded tumor tissue were blocked, 
incubated overnight at 4°C with the primary antibodies against IGF-1Rß (Santa Cruz), PTEN 
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(Cell Signaling), or HMB45 (DAKO), and stained with Cy3- or Cy5-conjugated donkey 
anti-rabbit or anti-mouse antibodies (Dianova). Nuclei were stained using YO-PRO-1 
(Invitrogen). Imaging was performed with a confocal laser microscope (Leica TCS SP). 
2.2.11 Stability assay 
For the stability assay, the melanoma cells (SKMEL19 and 1205LU) were pretreated with 2 
μg/ l doxycycline for the induction of the expression of BRAFV600E or the different PTEN 
forms (WT, G129E, Y138L, C124S) for 48 hours before cultivation in medium containing 150 
μg/ l cyclohexi ide (CHX) for the indicated ti e points (0, 3, 6,and 12 hours). To analyze 
the effect of the MEK inhibitor AZD6244 on protein stability, the cells were instead pretreated 
for 12 hours with the  EK inhi itor AZ 6244 (4 μ ). Cells were lysed with lysis  uffer (Cell 
Signaling Technology), and lysates were used to perform Western Blot analyses for the 
detection of IGF-1R in relation to beta-actin in order to determine the protein stability after 
inhibiting the protein de novo synthesis using CHX. 
2.3 Biochemistry 
2.3.1 Gene transcription 
2.3.1.1 RNA Extraction  
Total RNA was extracted from cells using NucleoSpin RNA (MACHERY-NAGEL) according 
to the instruction of the manufacturer. 
2.3.1.2 Measurement of the concentration of the isolated RNA/DNA 
The absorbance (A) of a diluted RNA sample is measured at 260 and 280 nm. The nucleic 
acid concentration is calculated using the Lambert-Beer-law, which predicts a linear change 
in absorbance with concentration. An A260 reading of 1.0 is equivalent to ~40 µg/ml 
single-stranded RNA. The A260/A280 ratio is used to assess RNA purity. An A260/A280 ratio 
of 1.8-2.1 is indicative of highly pure RNA. Instead, an A260 reading of 1.0 is equivalent to 
~50 µg/ml double-stranded DNA. The A260/A280 ratio of 1.8 is indicative of highly pure DNA. 
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2.3.1.3 Reverse Transcription 
Reverse transcriptase can use RNA as template to generate cDNA, which is used for 
semiquantitative detection of gene expression.  
1 µg of RNA was diluted in nuclease free water in a 0.5 ml-PCR-tube at a final volume of 24 µl. 
To denature RNA templates, the tube was incubated at 70°C for 5minutes, then immediately 
put on ice for at least 1 minute. At the same time a cDNA synthesis mix was prepared. 16 µl of 
the mix were added to each tube containing RNA templates. The tubes were mixed gently, 
and centrifuged briefly, then incubated for 10 minutes at 25°C, followed by 50 minutes at 
50°C for 1 hour. Finally the tubes were heated at 85°C for 5 minutes to terminate the 
reactions and chilled on ice. c NA synthesis reaction can  e stored at −20°C or used for CR 
immediately. 
Table 2: Reverse transcription 
RNA-Primer-Ansatz 
1 µg isolated RNA 
x µl add DNase/RNase free Water to 24μl 
Master mix for reverse transcription  
8 µl 5X buffer 
4 µl  DTT 
2.5 µl dNTPs  2 mM of each dNTP 
1 µl random hexamer primer 200ng/μl 
0,5 µl reverse transcriptase 200U/μl 
2.3.1.4 Quantitative Real-Time PCR (qRT-PCR) 
The real-time, fluorescence-based, quantitative polymerase chain reaction follows the 
general principle of polymerase chain reaction. The basis of this method is that binding of dye 
to ds DNA in PCR causes fluorescence of the dye. An increase in DNA product during PCR 
therefore leads to an increase in fluorescence intensity. Hence DNA concentrations can be 
quantified by the measuring fluorescence intensity at each cycle. In order to control the 
differences in RNA isolation and in the efficiency of the reverse transcription reaction from 
sample to sample and experiment to experiment, the specific gene being studied is quantified 
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in relation to another gene called a reference gene or housekeeping gene, which is selected 
for its almost constant rate of expression in both the control and experimental samples. 
qRT-PCR was performed with the LightCycler 480 SYBR Green System (Roche, Germany). 
The relative expression levels of IGF-1R or IGF-1 were determined by calculating the cycle 
threshold (Ct) values using the ∆∆Ct-method with GAPDH or 18S rRNA as a reference gene.  
2.3.2 Immunoblotting  
2.3.2.1 Cell lysate 
For lysis of adherent cells, cells were washed once with pre-chilled PBS. Appropriate amount 
of cold 1x lysis buffer (Cell signaling) was added onto cells. After 5 minutes incubation on ice, 
cells were scraped down by a cell scraper. The cell lysates were collected in a 1.5 ml tube, 
and sonicated briefly, then spinned 10 minutes at 14,000 gravity (g) in a cooled microfuge 
(Biofuge pico). The supernatant was collected for use. 
2.3.2.2 Measurement of protein concentration 
The Bradford assay, a colorimetric protein assay, is based on an absorbance shift of the dye 
Coomassie Brilliant Blue G-250. The binding of the dye to the protein stabilizes the blue 
anionic form and has an absorption spectrum maximum at 595 nm. The increase of 
absorbance at 595 nm is proportional to the amount of bound dye, and thus to the amount of 
protein present in the sample. 
The Bio-Rad solution was diluted 1:5 with distilled water. 2 µl of samples were added to 198 
μl of prepared Bio-Rad solution in a 96-well plate, which was measured using a microplate 
reader (Berthold) at 595 nm. To calculate the protein concentration of samples a standard 
curve is produced using a series of protein standards (BSA) diluted in water to final 
concentrations of 0 (Blank and Mackensen), 156.25, 312.5, 625, 1250 and 2500 µg/ml. 15 – 
30 μg of protein are used for immunoblotting. 
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2.3.2.3 SDS-polyacrylamide gel electrophoresis 
The binding of SDS to the polypeptide chain of protein imparts an even distribution of 
negative charge per unit mass, thereby resulting in a fractionation by approximate size during 
electrophoresis. 
A discontinuous polyacrylamide gel is composed of a lower layer (separating gel) for 
separation of polypeptides by size and an upper layer (stacking gel) including the sample 
wells, designed to compress protein in samples into micrometer thin layers when they reach 
the separating gel. The acrylamide concentration of the gel ranges from 5% to 15%. Lower 
percentage gels are better for resolving very high molecular weight molecules, while much 
higher percentages are needed to resolve smaller proteins.  
According to the size of detected proteins the SDS-gels with different concentration of 
separating gel are produced. Prior to electrophoresis the protein samples were combined 
with1x Laemmli buffer and heated at 95°C for 5 minutes, cooled and 15-30 µg protein per 
lane were loaded onto the prepared gels. Gels were running for 10 minutes at 70 voltages, 
followed by 90 minutes 120 voltages. 
Table 3: Production of SDS-Gels 
 Separating gel 
10% (20 ml) 
Separating gel 
12% (20 ml) 
Stacking gel 
(10 ml) 
H2O 9,575 ml 8,6 ml 7,225 ml 
40% Acrylamid 5,025 ml 6,0 ml 1,275 ml 
1,5 M Tris (pH 8,8) 5,0 ml 5,0 ml  
1,0 M Tris (pH 6,8)   1,25 ml 
10% SDS 200 µl 200 µl 100 µl 
10% Ammoniumpersulfat 
 (APS) 
200 µl 200 µl 100 µl 
TEMED 20 µl 20 µl 10 µl 
 
6x Laemmli buffer 
10 ml 1M Tris pH 6.8 
30 ml Glycerin 
12 g  SDS 
30 μl ß-Mercaptoethanol 
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50 μg Bromphenolblau 
add H2O to 100 ml 
 
5x Running buffer 
15.1 g Tris(base) 
94 g  Glycin 
5 g SDS 
add H2O to 1 litre 
2.3.2.4 Western Blot 
In order to make the proteins accessible to antibody detection, they are transferred from the 
gel onto a membrane made of nitrocellulose or polyvinylidene difluoride (PVDF). The proteins 
maintain the organization they had within the gel. Electrophoretic transfer is used due to its 
high speed and transfer efficiency. 
A protein-containing polyacrylamide gel was placed in direct contact with a piece of PVDF 
and 3 filter papers on top of that, then "sandwiching" this between two electrodes submerged 
in a conducting solution.  An electric field of 25 voltages was applied overnight so that the 
proteins move out of the polyacrylamide gel and onto the surface of the membrane, where 
the proteins become tightly attached.  
Since the membrane used in Western Blotting have a high affinity for proteins, after the 
transfer of the proteins from the gel, it is important to block the remaining surface of the 
membrane to prevent nonspecific binding of the detection antibodies during subsequent 
steps. The membranes were rinsed briefly with Tris-Buffered Saline with Tween 20 (TBST) 
buffer, then incubated with 5% non-fat dry milk in TBST buffer for at least 1 hour. Following 
blocking, the corresponding antibody, which recognizes a specific protein or epitope, was 
diluted in 5% milk buffer. Membranes were incubated overnight at 4°C with the antibody 
solution in a 50 ml tube under gentle agitation (RM5, Fröbel Labortechnik). At the next day 
the membranes were rinsed three times with TBST buffer, 10 minutes for each time. Because 
the primary antibody, which recognizes the target protein in a Western Blot, is not directly 
detectable, tagged secondary antibodies are used for detection. The secondary antibodies 
were also diluted in 5% milk buffer in a new 50 ml tube. Membranes were incubated at RT for 
1 hour with the secondary antibody; subsequently membranes were rinsed three times, 5 
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minutes for each time. Since the secondary antibodies were labeled with Horseradish 
peroxidase (HRP), chemiluminescent substrates are used. 700 µl of the substrates are 
added on each membrane, and then the membrane is sealed in plastic. Light signals are 
documented with X-ray film. Semi-quantification of western blots was done with the freeware 
software tool scion image (NIH image, http://rsb.info.nih.gov/nih-image/) by using the actin 
signal for normalization. 
Transfer buffer 
5.8 g Tris(base) 
2.9 g Glycin 
0.37 g SDS 
200 ml methanol 
add H2O to 1 litre 
 
TBST 
2.42 g Tris(base) 
8 g NaCl 
adjust to pH 7.6 with 1 N NaOH, RT 
add H2O to 1 litre 
add 1 ml Tween 20 
2.4 Molecular biology 
2.4.1 Transformation of competent E.coli with plasmids 
Competent E.coli bacteria were thawed on ice for 5 minutes, then 10 ng of plasmids were 
added. After mixing with pipette the mixture was incubated on ice for 20 minutes so that 
plasmids can attach to the competent cells. Subsequently the competent cells were heated at 
42°C for 90 seconds to create a thermal imbalance on either side of the cell membrane, 
which forces the DNA to enter the cells through either cell pores or the damaged cell wall. The 
cells were shortly put on ice again, before 1 ml of lysogeny broth (LB) medium was added to 
the cells. After growing at 37°C for 1hour, 200 µl of the cell suspension were plated on a 
LB-agar plate containing 50 µg/ml ampicillin. To obtain a great amount of desired plasmids, 
transformed bacteria are cultured in LB-medium with appropriate antibiotic overnight at 37°C 
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under gently agitation. 
LB Medium 
10 g  Trypton 
5 g  yeast extract 
5 g  NaCl  
add H2O to 1 litre 
 
LB-agar plates 
10 g Trypton 
5 g  yeast extract 
5 g  NaCl  
add 15 g Agar 
add H2O to 1 litre and autoclave 
use around 20 ml per plate 
2.4.2 Plasmid preparation 
To obtain a great amount of desired plasmids, transformed bacteria were cultured in 
LB-medium with appropriate antibiotic overnight at 37°C under gently agitation. The 
suspension of bacteria was centrifuged at 6000 rpm for 5 minutes at 4°C (Varifuge 3.0R). The 
pellet was resuspended in 4.5 ml of lysis buffer. 10 ml of 0.2 M NaOH with 1% SDS were 
added and mixed by inverting tubes several times. Under alkaline conditions (pH 12.0-12.5) 
both chromosomal DNA and protein are denatured, the plasmid DNA however, remains 
stable. Then, 7.5 ml of 3 M potassium acetate buffer were added to neutralize the pH-value of 
the solution so that the large and less supercoiled chromosomal DNA and proteins precipitate, 
but the small bacterial DNA plasmids stay in solution. After incubation on ice for 15 minutes, 
the mixture was centrifuged for 5 minutes at 6000 rpm and 4°C (Varifuge 3.0R). The 
supernatant was filtered through a piece of gauze into a new 50 ml tube. To precipitate 
plasmid, 13.5 ml of isopropanol were added. After incubation for 15 minutes at RT, the 
solution was centrifuged for 10 minutes at 6000 rpm and 4°C (Varifuge 3.0R). The pellet was 
briefly dried, then resuspended in 2 ml of TE buffer. To precipitate RNA and small broken 
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pieces of genomic DNA, 2 ml of 4 M LiCl were added. The solution was mixed and incubated 
on ice for 5 minutes, then centrifuged for 5 minutes as before. The supernatant was collected 
in a new 15 ml tube, and 10 ml of pre-chilled 100% ethanol were added to precipitate 
plasmids. The tube was placed at -20°C overnight. At the next day plasmids were pelleted by 
centrifugation for 5 minutes at 6000 rpm and 4°C (Varifuge 3.0R). After washing with 70% 
ethanol and drying briefly, pellet is resuspended in 500 µl of TE buffer. 5 µl of RNase were 
added to degrade the remaining RNA, which is co-precipitated with plasmids. After 
incubation for 30 minutes at 37°C, 50 µl of 3 M sodium acetate pH 5.6 were added. To 
dissolve and denature proteins, 550 µl of phenol/chloroform  
(phenol:chloroform:isoamylalkohol, 25:24:1) were added. After strongly shaking for 2 
minutes, the solution was centrifuged for 3 minutes at 13000 rpm and 4°C (Biofuge pico). As 
much as possible from the upper water phase which is containing plasmids was collected in a 
new 1.5 ml tube, and the procedure of purification was repeated again. Then 400 µl of 
chloroform were added to the collected water phase. After shaking and centrifuging, the 
upper water phase was transferred into a new 1.5 ml tube. 250 µl of isopropanol were added 
to precipitate plasmids. After incubation for 5 minutes at RT plasmids were pelleted, washed 
with 70% ethanol, and dried at 37°C. Then the plasmids were resuspended in an appropriate 
volume of Tris-EDTA (TE) buffer.  
Lysis buffer 
50 mM  Glucose 
25 mM  Tris/HCl pH 8 
10 mM  EDTA 
 
Potassium acetate buffer 
29.4 g  KCH3COO  
5 ml    CH3COOH  
add     H2O to 100 ml 
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TE buffer 
10 mM  Tris/HCl pH 8 
1 mM    EDTA 
2.4.3 Sequencing 
Sequencing analyzes the order of individual nucleotides present in molecules of DNA or RNA, 
which has become indispensable for basic biological research, and in numerous applied 
fields such as medical diagnosis, biotechnology, forensic biology, virology and biological 
systematics.  
In 1977, Frederick Sanger and colleagues developed Didesoxy Sequencing or chain 
termination, based on the use of didesoxynucleotides in addition to the normal nucleotides  
found in DNA. Due to lack of a 3'-OH group, integration of these modified nucleotides into a 
sequence prevents the addition of further nucleotides, because a phosphodiester bond 
cannot form between the dideoxynucleotide and the next incoming nucleotide, and therefore 
the DNA chain is terminated. These chain-terminating nucleotides may be radioactively or 
fluorescently labeled for detection in automated sequencing machines. 
BRAF, PTEN and mutants were cloned into inducible lentiviral vectors (PLVX-tight-PURO, 
Clontech) by using In-fusion-H  Liquid Kits (Clontech) according  anufacturer’s protocol 
and Sanger-sequenced for verification (GATC Biotech, Konstanz, Germany). 
2.4.4 Gel electrophoresis  
Due to carrying negatively charged oxygens in the phosphate groups in the DNA backbone 
DNA molecular has an overall negative charge. In an electric field it moves towards the 
positive pole of the electrophoresis chamber. As it moves through the pores of the agarose 
matrix, the smaller one migrates faster and further over a given period of time than do the 
larger. Therefore DNA molecular can be separated by size. 
1 mg of agarose was added to 100 ml of Tris-Borate-EDTA (TBE) buffer. It was heated in 
microwave until agarose was dissolved completely. 10 µl of Gelred were added to the 
solution, then it was poured into a 35 ml gel form and combs for slot formation were added.  
After solidification the prepared 1% gel was merged in TBE buffer, then PCR products were 
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mixed with loading dye and loaded into the slots of the agarose gel. The gel runs for 1 hour at 
RT with 120 voltages. Under UV-light (280 nm) the PCR product is visible and was cut out for 
gel extraction. 
 10 X TBE buffer 
9 M Tris-Base 
9 M Boric acid 
250 mM EDTA 
2.4.5 Gel extraction 
The PCR products are extracted from agarose gel using Qiagen extraction kit according to 
the instruction. 
2.4.6 Restriction digest  
Restriction enzymes cut DNA at or near specific recognition nucleotide sequences known as 
restriction sites. Restriction digest is most commonly used as part of the process of the 
molecular cloning of DNA fragment into a vector (such as a cloning vector or an expression 
vector) which contains a multiple cloning site with many restriction sites nearby. 
In order to clone desired genes into PLVX-tight-puro vector, vector was digested with a 
combination of restriction enzymes (BMHI and EcoRI). For digestion the latter were pipetted 
together. The mixture was incubated at 37°C for 2 hours, and after separation by gel 
electrophoresis digested vectors or inserts were purified by gel extraction. 
Mixture of digestion 
1.5 μg   L X-tight-puro vector Plasmid 
2 μl      BMHI 
1 μl      EcoRI 
4 μl     10x Tango buffer 
add H2O to 20 μl 
2.4.7 In fusion cloning 
With In-Fusion HD Cloning Plus System (Clontech) any oligo/PCR fragment (20 bp to 15 kb) 
or multiple fragments can be directionally cloned into any linearized vector in a single reaction. 
Firstly, single-stranded regions at the ends of the oligo/PCR insert and linearized vector are 
created by the In-Fusion enzyme. Through base pairing of the complementary regions on the 
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insert and vector DNA molecules they are spontaneously annealed. Any single-stranded 
gaps of the annealed DNA are repaired when they are transformed into Escherichia coli, 
therefore resulting in the synthesis of a recombinant vector containing the oligo/PCR insert. 
This system allows sequence and restriction site-independent cloning. No vector 
dephosphorylation, blunt-end polishing, or PCR fragment digestion is required.  
cDNAs of IGF-1R, BRAF, PTEN and individual mutants are used as template for PCR 
amplification. Double digested vector and PCR products are separated by gel 
electrophoresis and purified by gel extraction. In-fusion reaction is done according 
 anufacturer’s protocol. Mutated BRAF cDNA sequence was a generous gift from Sebastian 
Haferkamp (Würzburg, Germany). PTEN and PTEN mutant cDNA sequence were kindly 
provided by Nick Leslie (Heriot-Watt University, Edinburgh, UK). IGF-1R cDNA sequence 
was bought from ORIGENE. Wild-type BRAF cDNA sequence was amplified by using 
Human Multiple Tissue cDNA (MTC) Panel II (Clontech). 
Table 4: cloning PCR 
Reagent Volume 
CloneAmp HiFi PCR Premix 
Primer 1 
Primer 2 
Template (cDNAs) 
Sterilized distilled water 
12.5 µl 
5 pmol 
5 pmol 
100 ng 
up to 25 µl 
PCR Reaction 
98°C 10 second 
55°C 5 or 15 second         30–35 cycles (3-step PCR) 
72°C 30–60 second/kb 
2.4.8 Inducible expression of target gene in melanoma cells 
The Tet-On Gene Expression Systems were described by Gossen et al. (Gossen, Freundlieb 
et al. 1995). It allows researchers to regulate gene expression in a quantitative manner. 
The Lenti-X Tet-On Advanced Inducible Expression System contains two critical 
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components: the Regulator Vector: pLVX-Tet-On Advanced and the Response Vector: 
pLVX-Tight-Puro. The pLVX-Tet-On advanced vector constitutively expresses the 
tetracycline-controlled transactivator, rtTA-Advanced.  At present of doxycycline it binds to 
the inducible promoter (PTight), which controls expression of your gene of interest, and 
further activates transcription of the downstream gene. 
 
Figure 12: Gene induction in the Tet-On Advanced System by Clontechniques. *Dox: doxycycline 
To establish the complete Tet-On Advanced System, melanoma cells were firstly transduced 
with Lentiviral vector expressing rtTA-Advanced. The transduced cells were cultured under 
selection with 200 µg/ml G418 until non-transduced cells were completely killed. Sequently 
the transduced cells were transduced again with lentiviral vector, pLVX-Tight-Puro containg 
target genes. The transduced cells were selected again with 10 µg/ml puromycin to kill 
non-doubly-transduced cells. The established dual transduced cells were used for inducible 
expression of target gene. 
2.5  Statistical analysis 
Data are presented as mean ± s.e.m (standard error of measurement) for at least three 
independent experiments. Statistical analysis was performed with a two-tailed unpaired t test, 
unless otherwise stated. P values of <0.05 were considered to be statistically significant, and 
P values of <0.01 were considered as highly significant (* presents P-value<0.05; ** presents 
P-value<0.01; *** presents P-Value< 0.001). 
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3 Results 
3.1 IGF-1R expression correlates with expression of PTEN in human melanoma cells  
We analyzed expression of IGF-1R in different human melanoma cell lines by qRT-PCR and 
western blot analyses, and compared it with normal human melanocytes. IGF-1R was 
significantly upregulated both at the mRNA and the protein level in most of the melanoma cell 
lines examined compared to normal melanocytes (Figure 13A and B). 
Interestingly, we also found that among the different melanoma cell lines the IGF-1R 
expression level is positively correlated with PTEN expression. PTEN negative melanoma 
cell lines expressed significantly lower levels of IGF-1R on protein as well as on RNA level 
than the PTEN positive cell lines (Figure 13A and B).  
Due to loss of PTEN, which negatively regulates the PI3K/AKT signaling pathway, the activity 
of PI3K/AKT signaling as measured by levels of pAKT is significantly higher in PTEN 
non-expressing melanoma cells than in PTEN expressing melanoma cells (Figure 13A and 
B). Additionally, we confirmed that there was no correlation between IGF-1R expression and 
activity of the MAPK signaling pathway, which is mostly mutationally activated in melanoma 
cells, as measured by pERK levels (Figure 13A).  
To determine the level of IGF-1R expression in tissues, we performed semiquantitative 
immunofluorescence analyses of tissue sections of metastases derived from 35 melanoma 
patients. The results indicate that in several samples, similar to the expression in melanoma 
cell lines in vitro, IGF-1R expression in vivo correlated with PTEN expression in the 
melanoma tissue samples (Figure 13C). This does not reach significance, probably because 
only few melanoma cells indeed expressed PTEN at higher levels (Figure 13C).  
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Figure 13: IGF-1R expression correlates with PTEN expression in vitro and in vivo. 
(A) 15 different human melanoma cell lines differing in PTEN expression and normal human melanocytes 
(NHMs) were cultured in RPMI medium for 72 hours. The cell lysates were harvested and immunoblotted with 
the indicated antibodies. (B) The protein expression of pAKT or IGF-1Rß shown in (A) was normalized to ß-actin 
(two left panels) or relative RNA expression level of IGF1R determined by qRT-PCR (right panel) in PTEN 
positive or negative cell lines. RNA expression of IGF-1R in the melanoma cell lines was normalized to the 
expression level in NHM set as 1. Statistical analysis was done by a Mann Whitney test and stars indicate 
significant differences. P-value of IGF-1R mRNA expression is 0.0003. P-value of IGF-1R protein expression is 
0.0401. P-value of pAKT protein expression is 0.0007. (C) Shown is protein expression of PTEN (red) and 
IGF-1R (blue) in paraffin-embedded human tissue sections of two PTEN high and PTEN low expressing 
melanoma metastases assessed by representative confocal laser scanning immunofluorescence assay. Nuclei 
were stained with YOPRO (green). Bottom: 35 biopsies of melanoma metastases were stained as shown in (C), 
and the level of IGF-1R and PTEN expression were determined using a scoring system ranging from: 0: absent, 
1: low expression, 2: medium to 3:high expression. There was no significant correlation between PTEN and 
IGF-1R expression. For statistical analysis, a Kruskal–Wallis with  unn’s post-test has been done. 
3.2 PTEN increases the sensitivity of melanoma cells towards IGF-1R inhibition 
 IGF-1R plays an important role in tumorigenesis, resistance to apoptosis and resistance to 
anti-cancer agents (Tao, Pinzi et al. 2007; Casa, Dearth et al. 2008; Pollak 2008). IGF-1R 
has gained increasing attention as a promising target in cancer therapy, but its role as a 
therapeutic target in melanoma has not been systematically explored yet. We used an 
allosteric inhibitor of IGF-1R, PPP in a panel of melanoma cell lines with PTEN expression or 
not and determined their IC50, at which 50% of cell growth is inhibited, using a cell growth 
assay using 4-methylumbelliferrone as a substrate (Figure 14A). Unlike ATP competitive 
inhibitors, PPP exhibits little effect towards IR (Vasilcanu, Girnita et al. 2004). It has been 
shown that in uveal melanoma cells with upregulation of the IGF-1R signaling pathway, PPP 
causes tumor regression and attenuates mechanisms involved in invasion (Girnita, Girnita et 
al. 2004; Girnita, All-Ericsson et al. 2008). However, cutaneous melanoma cell lines have a 
different sensitivity to the IGF-1R inhibitor. PTEN positive melanoma cells are significantly 
more sensitive to IGF-1R inhibition as the PTEN-negative melanoma cell lines (Figure 14C). 
PTEN-expressing normal human melanocytes (NHMs) are as sensitive as the 
PTEN-negative human melanoma cell lines (Figure 14C). PPP induces an activation 
loop-specific inhibition of tyrosine phosphorylation of the IGF-1R (Vasilcanu, Girnita et al. 
2004). Thus, the auto-phosphorylation of IGF-1R is suppressed by the PPP in all cells tested, 
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no matter how their sensitivity towards PPP is (Figure 14D). Surprisingly, expression of 
IGF-1R is dramatically decreased by PPP only in melanoma cells, which lost PTEN 
expression (Figure 14D). Interestingly, re-expression of PTEN in the PTEN negative 
melanoma cell line SKMEL147 led to stabilization of IGF-1R expression after PPP treatment 
and increased sensitivity towards IGF-1R inhibition (Figure 14E). PTEN re-expression did not 
affect proliferation of the melanoma cells (Figure 14B). These data suggested that PTEN 
negative melanoma cells escape IGF-1R blockade by further down-regulation of the receptor 
and if PTEN is present it stabilizes IGF-1R expression and thereby increases sensitivity 
specifically towards IGF-1R blockade.   
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Figure 14: PTEN expression sensitizes melanoma cells towards IGF-1R inhibition. 
(A) The cell viability of MDA-MB435 (PTEN positive) and SKMel147 (PTEN negative) was assessed by MUH 
assay after 72 hours of treatment with PPP (0.01-32 µM). The IC50 of PPP was calculated by GraphPad 
analyse as shown here. (B) The relative proliferation of SKMel147 melanoma cells, in which PTEN expression 
was induced by treatment with either 2 or 4 µg/ml doxycycline, was assessed by MUH assay. PTEN induction 
didn´t dramatically influence cell proliferation. (C) The cell viability of PTEN positive and PTEN negative human 
melanoma cell lines and NHM was assessed by MUH assay after 72 hours of treatment with PPP (0.01-32 µM). 
The results are expressed as IC50 of PPP, as shown at the left panel. For statistical analysis, a Mann Whitney 
test has been done. P-value is 0.0079. (D) Cells were treated with 1μ      for 24 hours, and the cell lysates 
were immunoblotted with the indicated antibodies. (E) In order to induce PTEN expression in SKMEL147, the 
cells were treated with 4 μg/ l doxycycline (+) or not (-) as control for 2 days. After that, the cells were treated 
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with 1μ      (+) or not (-) for 24 hours, and the cell lysates were immunoblotted with the indicated antibodies, 
as shown at the left panel. The right panel showed the mean IC50 value from triplicate experiments. For 
calculating IC50, the cell viability of SKMel147 melanoma cells, in which PTEN was either induced (+) by adding 
4 μg/ l doxycycline or not (-) for 2 days, was assessed by MUH assay after 72 hours of treatment with PPP 
(0.01-32 µM). For statistical analysis, a Mann Whitney test has been done. P-value is 0.0204. 
3.3 The phosphatase activity of PTEN increases IGF-1R protein expression in 
melanoma cells 
To clarify if PTEN regulates IGF-1R expression, we transduced A375 cells via lentiviral gene 
transfer to express a specific shRNA against PTEN and analyzed changes in the expression 
of IGF-1R. We found that reduction of PTEN protein levels reduced IGF-1R expression 
(Figure 15A). In contrast, re-expression of PTEN, using a doxycycline-inducible lentiviral 
gene transfer, in the PTEN negative human melanoma cell lines SKMEL147 and 1205LU 
results in a lag increase of IGF-1R expression and in accordance with the role of PTEN, 
negatively regulating PI3K/AKT pathway, PTEN expression also decreases the level of pAKT 
(Figure 15B). Our data indicates that IGF-1R expression is directly regulated by PTEN. 
Further we checked the mechanism by which PTEN regulated IGF-1R expression. As PTEN 
has dual phosphatase activity, we used 3 PTEN mutants, designed by Nick Leslie, the 
PTENG129E mutant lacking the lipid phosphatase activity, but which retains the protein 
phosphatase activity of the enzyme (Lackey, Barnett et al. 2007), the PTENY138L lacking the 
protein phosphatase activity, but retaining the lipid phosphatase activity (Davidson, Maccario 
et al. 2010), and PTENC124S, which lacks both types of phosphatase activities (Davidson, 
Maccario et al. 2010), and established inducible expression of these mutants and wild-type 
PTEN in SKMEL147 cells. Interestingly, we found that expression of wild-type PTEN induces 
IGF-1R expression as shown before, but neither of single or both phosphatase-deficient 
mutants were able to significantly increase expression of the IGF-1R, even single 
phosphatase-deficient PTEN species decreased its expression (Figure 15C). The similar 
effect was seen in 1205LU cells overexpressing wild-type or mutant PTEN forms. IGF-1R 
expression was not comparably induced with mutant PTEN expression as much as with 
expression of the wild-type PTEN form (Figures 15F). Further we checked the effect of PTEN 
expression on the transcription level of IGF-1R. Also on transcript level we do see either no or 
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only an up to two-fold increase in IGF-1R mRNA expression after overexpression of wild-type 
PTEN (Figure 15D and 15G). This is not enough to explain the more than 7-fold higher 
protein expression of the IGF-1R (Figures 15C and 15F). In addition, the expression of 
wild-type PTEN, but not of the mutant forms, increased surface expression of the IGF-1R 
(Figure 15E). From these results, we postulated that PTEN is able to increase IGF-1R 
expression in melanoma cells by increasing protein stability of the IGF-1R and this is 
dependent on the phosphatase activity of PTEN. To address this point, we inhibited protein 
de novo synthesis with addition of CHX, and analyzed the stability of the IGF-1R in 1205LU 
melanoma cells, in which wild-type or mutant PTEN had been inducibly re-expressed for 2 
days. We analyzed the expression of IGF-1R by Western blot analyses in a time course after 
CHX treatment. Unlike the expression of the pro-IGF-1R form, expression of IGF-1R was 
very stable, and does not change significantly during the CHX treatment irrespective of PTEN 
expression (Figures 15H). Therefore, our results indicate that the stability of IGF- 1R is not 
significantly different after wild-type or mutant PTEN overexpression (Figures 15H). We 
conclude that the reason for the higher expression of IGF-1R after wild-type PTEN 
expression is not a stabilization of the IGF-1R protein and might be achieved by a 
combination of enhanced IGF-1R transcription and increased protein shuttling, and the 
phosphatase activity of PTEN seems to be required for this. 
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Figure 15: The phosphatase activity of PTEN increases IGF-1R protein expression. 
(A) Control shRNA or shRNA against PTEN was transduced into A375 melanoma cells with a lentivirus 
expressing system. After 72 hours of the transduction, transduced cells, which co-expressed GFP, were sorted 
and cultured. After additional 48 hours, the cell lysates were harvested and immunoblotted with the indicated 
antibodies. (B)  TEN was induced to express in 1205LU and SK EL147  elano a cells  y adding 4 μg/ l 
doxycycline at the indicated time, and then the cell lysates were harvested and immunoblotted with the indicated 
antibodies. (C, F) wild-type PTEN or the mutants PTEN
G129E
, PTEN
Y138L
 or PTEN
C124S
 lacking defined 
phosphatase activities was induced to express in SKMel147 (C) and 1205LU (F) melanoma cells. After 48 hours 
of induction, the cell lysates were harvested and immunoblotted with the indicated antibodies. The protein 
expression of IGF-1R shown in (F) is normalized to ß-actin, and then the ratio to individual control was 
determined. (D, G) The relative RNA expression level of IGF1R was determined by qRT-PCR. The different 
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forms of PTEN were induced to express in SKMel147 (D) and 1205LU (G) melanoma cells for 48 hours, and 
then RNA was prepared for qRT-PCR to detect IGF-1R and 18S rRNA expression. Shown is the relative RNA 
expression of IGF-1R before (-) or after (+) PTEN induction by adding doxycycline (4 µg/ml). NS: non-significant. 
(E) The surface expression of IGF-1R in 1205Lu melanoma cells after 48 hours of induction of expression of 
wild-type or mutant PTEN forms was assessed by flow-cytometric analyses. Filled grey field denotes the isotype 
control staining. (H) The stability of IGF-1R and pro-IGF1R was assessed in 1205LU melanoma cells after 
induction of expression of wild-type or mutant PTEN. After 48 hours of the induction of PTEN expression, cells 
were cultured in ediu  containing 150 μg/ l CHX to inhi it the protein de novo synthesis for the indicated time 
points. Cell lysates were harvested and immunoblotted with the indicated antibodies to detect IGF-1R and its 
pro-form in relation to beta-actin.  
* The experiments of E, F-H have been done by Heike Niessner and Tobias Sinnberg. 
3.4 The regulation of IGF-1R expression is independent on PI3K and AKT activity in 
melanoma cells 
It has been described that IGF-1R expression can be regulated in mouse embryonic 
fibroblasts or in a glioblastoma cell line by a negative feedback mechanism of activated 
PI3K/AKT pathway (Lackey, Barnett et al. 2007; Qin, Li et al. 2009; Chandarlapaty, Sawai et 
al. 2011). To confirm that, we next investigated the effects of modulation of PI3K/AKT 
pathway activity on IGF-1R expression. Firstly, we examined the effect of PI3K/AKT inhibition 
using the inhibitor PI103, BKM120, and GDC0941 and the AKT inhibitor ipatasertib (AKTi) in 
the PTEN positive melanoma cell lines A375 and MDAMB435 and the PTEN negative 
melanoma cell lines SKMEL147 and 1205LU on IGF-1R expression by western blot analyses. 
Treatment with PI3K inhibitors efficiently reduced PI3K/AKT signaling activity in all cell lines 
already 1 day after treatment as measured by pAKT levels, whereas the AKT inhibitor 
increased pAKT levels presumably by a positive feedback mechanism (Figure 16A). None of 
the treatments resulted in elevated expression of IGF-1R in melanoma cell lines (Figure 16A). 
Consistent with our results, knockdown of AKT3, the dominant isoform of AKT, in the PTEN 
expressing melanoma cell line A375 or the non expressing cells 1205LU and SKMEL147, 
using specific siRNA, had an inhi itory effect on AKT phosphorylation,  ut didn’t increase 
IGF-1R expression (Figure 16B). Inversely, overexpression of the AKT3 in melanoma cells 
A375, 1205LU, or SKMEL147 led to increased phosphorylation of AKT, but had no significant 
effect on IGF-1R expression (Figure 16B). Together these data suggest that in contrast to 
studies with mouse embryonic fibroblasts and glioblastoma cells (Lackey, Barnett et al. 2007; 
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Qin, Li et al. 2009; Chandarlapaty, Sawai et al. 2011), IGF-1R expression is independent on 
the activity of PI3K/AKT pathway in melanoma cells. 
 
Figure 16: IGF-1R expression doesn’t greatly depend on the activity of the PI3K/AKT signalling pathway 
in melanoma cells. 
(A) The PTEN positive melanoma cell lines A375 and MDAMB435 and the PTEN negative melanoma cell lines 
1205LU and SKMEL147 were treated with AKT inhibitor ipatasertib (AKTi: 0.5 μ ), the class I pan-PI3K inhibitor 
 uparlisi  (BK 120: 1 μ ), the class I  I3K inhi itor pictilisi  24(G C0941: 1 μ ) and the  I3-Kinase inhibitor 
 I103 (2.5 μ ) or  SO for 24 hours and the cell lysates were immunoblotted with the indicated antibodies. (B) 
Scrambled siRNA or siRNA against AKT3 for downregulation of AKT3 expression (left blot) or a control vector or 
Myr-HA-AKT3 plasmid for overexpression of AKT3 (right blots) was transfected into the PTEN positive 
melanoma cell lines A375 and the PTEN negative melanoma cell lines 1205LU and SKMEL147. After 48 hours 
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of transfection, the cell lysates were harvested and immunoblotted with the indicated antibodies. 
* Heike Niessner has done the experiments of A. 
3.5 BRAF enhances IGF-1R expression independent on MAPK signaling activity 
Due to an activating BRAFV600E mutation, MAPK signaling is constitutively activated in about 
half of all melanoma patients (Davies, Bignell et al. 2002). Targeting BRAFV600E with the 
BRAF inhibitor PLX4032, which inhibits specifically BRAFV600E, leads to tumor shrinkage and 
PFS of 7 months in patients with BRAFV600E mutant melanomas (Flaherty, Puzanov et al. 
2010). A publication showed that after chronic treatment with PLX4032, melanoma cells 
could acquire resistance to the BRAF inhibitor, mediated by upregulation of IGF-1R/PI3K 
signaling (Villanueva, Vultur et al. 2010). On the contrary, another publication showed that 
stimulation with IGF-1, the cognate ligand for IGF-1R, cannot confer initial resistance against 
PLX4032 treatment to melanoma cells (Straussman, Morikawa et al. 2012). It seems that 
IGF-1R signaling has a complex role in the treatment with PLX4032. Actually, it is also 
possible that IGF-1R expression is regulated differently by targeting BRAF upon short-term 
exposure to PLX4032. To confirm this hypothesis, we treated the human melanoma cell line 
SKMEL19, harboring a BRAFV600E mutation, with the inhibitor PLX4032. To preclude the 
off-target effect, we also used MV3, which has wild-type BRAF. The result showed that in 
SKMEL19 PLX4032 was effective in reducing pERK levels already 1 hour after treatment 
(Figure 17A). Interestingly, we also found that the IGF-1R protein expression was decreased, 
starting at 18 hours after addition of PLX4032, accompanied by a reduction of pAKT levels 
(Figure 17A), whereas PLX4032 did not affect IGF-1R expression and pERK levels in the 
melanoma cell line MV3 (Figure 17A). In addition, surface expression of the IGF-1R, where it 
comes in contact with its cognate ligand and mediates downstream signaling transduction, 
was also reduced after PLX4032 treatment in SKMEL19, but not MV3 (Figure 17B). This 
effect on IGF-1R surface expression could be reproduced in two other melanoma cell lines 
carrying either mutated or wild-type BRAF, respectively (Figure 17B bottom). PLX4032 
treatment resulted in down-regulation of IGF-1R expression already on transcriptional level 
and was evident in several BRAF-mutated melanoma cell lines, but not in those carrying 
wild-type BRAF (Figure 17C). These data indicate that unlike in resistant melanoma cells, not 
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only the total expression of IGF-1R but also the localization on the cell membrane were 
strongly decreased in melanoma cells after initial treatment with PLX4032. Further we asked 
whether the decreased expression of IGF-1R is dependent on the activity of the MAPK 
pathway or not. We inhibited MAPK-signaling using AZD6244, an inhibitor of MEK, which is a 
downstream component of BRAF in the MAPK pathway. Interestingly, we found that neither 
IGF-1R surface expression nor total IGF-1R protein expression in the melanoma cells tested 
in this assay, were decreased by inhibition of MAPK pathway by AZD6244 (Figure 17E and 
17D). These data suggest that IGF-1R expression and activity is regulated by BRAF, which is 
independent on MAPK signaling activity. To proof this we down-regulated BRAF in SKMEL19 
or MV3 melanoma cells lines carrying either wild-type or mutated BRAFV600E, respectively. In 
both cell lines down-regulation of BRAF decreases IGF-1R expression (Figure 17F). In 
addition, up-regulation of either BRAFV600E or wild-type BRAF using a doxycycline-inducible 
system in SKMEL19 melanoma cells increased IGF-1R expression already 1 day after BRAF 
induction (Figure 17F). Moreover, BRAFV600E overexpression in SKMEL19 melanoma cells 
resulted in higher IGF-1R surface expression (Figure 17G). The RNA expression of IGF-1R 
after BRAFV600E overexpression was not affected (Figure 17H). As the studies described 
above, we performed stability assays using CHX treatment of SKMEL19 melanoma cells with 
or without BRAFV600E overexpression or after AZD6244 treatment. The results indicate that 
after BRAFV600E overexpression, the stability of IGF-1R is increased (Figures 17I), whereas 
MEK inhibition using AZD6244 treatment of the cells did not significantly change protein 
stability of IGF-1R (Figures 17J). These data indicate that IGF-1R protein expression is 
positively regulated by BRAF and independent of pERK levels in melanoma cells, 
presumably by increased protein stability.  
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Figure 17: BRAF enhances IGF-1R expression in a MAPK signalling activity independent manner. 
(A) The BRAF
V600E
 melanoma cell line SKMEL19 and the BRAF wild-type melanoma cell line MV3 were treated 
with the BRAF
V600E
 inhibitor PLX4032 (1 µM) for the indicated time points, and the cell lysates were harvested 
and immunoblotted with the indicated antibodies. (B) The surface expression of IGF-1R in indicated melanoma 
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cells in untreated (control) cells or cells treated for 24 hours with PLX4032 (1 µM) were assessed by 
flow-cytometric analyses. Filled grey field denotes the isotype control staining. (C) Shown is relative mRNA 
expression of the IGF-1R in the indicated melanoma cell lines expressing either wild-type or mutated BRAF
V600E
 
after treatment with PLX4032 (1 µM) for 6 hours. RNA expression was assessed by qRT-PCR and normalized to 
the respective untreated cells. (D) The surface expression of IGF1R in SKMEL19 or MV3 melanoma cells, which 
were either untreated or treated with the MEK inhibitor AZD6244 (4 µM) for 24 hours, by flow-cytometric 
analyses. Filled grey field denotes the isotype control staining. (E) The melanoma cell lines SKMEL19 and 
Malme3M (PTEN positive) and 1205LU and SKMel147 (PTEN negative) were treated with the MEK inhibitor 
AZD6244 (4 µM) for 24 hours. The cell lysates were harvested and immunoblotted with the indicated antibodies. 
(F) Left panels: scramble siRNA or siRNA against BRAF was transfected into SKMEL19 (BRAF
V600E
) or MV3 
(wild-type BRAF) melanoma cells. After 48 hours of transfection, the cell lysates were harvested and 
immunoblotted with the indicated antibodies. Right panel: either wild-type BRAF or BRAF
V600E
 was 
overexpressed in SKMEL19 melanoma cells in an inducible manner by adding 4 µg/ml doxycycline. After 24 
hours of transfection, cell lysates were harvested and immunoblotted with the indicated antibodies. (G) The 
surface expression of IGF-1R on SKMEL19 cells after 48 hours of inducible overexpression of BRAF
V600E
 (red) 
compared to the non-induced cells (blue) were assessed by flow-cytometric analyses. Filled grey field denotes 
the isotype control staining. (H) Shown is relative mRNA expression of IGF1R after the induction of expression 
of BRAF
V600E 
in SKMEL19 by adding doxycycline (2 μg/ l) for 48 hours. (I)The stability of IGF-1R was assessed 
in SKMEL19 melanoma cells after overexpression of BRAF
V600E
. After 48 hours of the induction of BRAF
V600E
 
expression, cells were cultured in ediu  containing 150 μg/ l CHX to inhi it the protein de novo synthesis for 
the indicated time points. The cell lysates were harvested and immunoblotted with the indicated antibodies to 
detect IGF-1R and its pro-form in relation to beta-actin. (J) Stability assay of IGF1R described as in (I) but cells 
were pre-treated with the  EK inhi itor AZ 6244 (4 μ ) for 12 hours.  
* The experiments of G-J have been done by Heike Niessner and Tobias Sinnberg. 
3.6 Activation in addition to up-regulation of the IGF-1R in melanoma cells increase 
therapy resistance  
Despite of regulation of IGF-1R by BRAF, we addressed the functional relevance of the 
IGF-1R expression and activation concerning resistance towards the BRAFV600E inhibitor 
PLX4032. First, we down-regulated the IGF-1R in SKMEL19 melanoma cells using specific 
siRNA and analyzed the percentage of cells, which have undergone apoptosis after 
treatment with increasing doses of PLX4032. Intriguingly, down-regulation of the IGF-1R 
sensitized melanoma cells towards PLX4032 treatment (Figure 18A). Vice versa, 
over-expression of IGF-1R increased resistance towards PLX4032 by decreasing apoptosis. 
Interestingly, additional stimulation of the cells by IGF-1 furthermore increases resistance 
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towards PLX4032 treatment (Figure 18B). This effect could be verified by a fluorescence 
based proliferation assay (Figure 18C). These data indicate that IGF-1R increases resistance 
towards PLX4032 and this effect is enhanced when the receptor is stimulated by its ligand 
IGF-1. 
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Figure 18: Activation of up-regulated IGF-1R in melanoma cells increases therapy resistance. 
(A) Left: either scrambled siRNA or siRNA against IGF-1R was transfected into SKMEL19 melanoma cells. After 
48 hours of transfection, cell lysates were harvested and immunoblotted with the indicated antibodies. Right: 
apoptosis was assessed by sub-G1 fraction of the cells. After 48 hours of transfection with either scrambled 
siRNA or siRNA against IGF-1R, the cells were then treated with increasing doses of PLX4032 for additional 2 
days. The percentage of cells in sub-G1 cell cycle phase was determined with the help of PI staining and flow 
cytometric analyses. Data are presented as the mean of sub-G1 fractions from triplicate experiments. (B) Left: 
the overexpression of IGF-1R in SKMEL19 melanoma cells was induced by adding doxycycline (4 µg/ml) for 24 
hours. The cell lysates were harvested and immunoblotted with the indicated antibodies. Right: apoptosis was 
assessed by sub-G1 fraction of the cells. The overexpression of IGF-1R in SKMEL19 melanoma cells was 
induced by adding doxycycline (4 µg/ml) for 24 hours. The cells were then treated with PLX4032 (1µM) alone or 
in combination with 100 ng/ml IGF-1 for additional 72 hours. The percentage of cells in sub-G1 cell cycle phase 
was determined with the help of PI staining and flow cytometric analyses. Data are presented as the mean of 
sub-G1 fractions from triplicate experiments. Compared to control, P value of IGF-1 is 0.0706. P value of 
doxycycline is 0.0015. P value of IGF-1 with doxycycline is <0.0001. (C) The cell viability was assessed by MUH 
assay after treatment with increasing doses of PLX4032 alone or in combination with 100 ng/ml IGF-1 for 72 
hours. Before PLX4032 treatment IGF-1R expression was either induced to overexpress in cells by addition of 4 
µg/ml doxycycline for 24 hours or not. 
3.7 Dermal fibroblasts mediate up-regulation of the IGF-1R by cell-cell contact and 
increase therapy resistance 
Although stimulation with IGF-1 alone is not enough to protect melanoma cells from PLX4032 
treatment, we reasoned that a way how to achieve innate therapy resistance of melanoma 
cells in a physiological situation must be mediated by activation and up-regulation of the 
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IGF-1R by micro-environmental signals. Melanoma cells can stimulate the recruitment of 
fibroblasts and activate them, resulting in melanoma cell growth by providing both structural 
(extracellular matrix proteins), and chemical support (growth factors), and conferring 
treatment resistance to melanoma cells as well (Flach, Rebecca et al. 2011). Therefore, we 
proposed that interaction of melanoma cells with human primary fibroblasts modulates 
IGF-1R expression and resistance towards PLX4032. To confirm this hypothesis, we 
co-cultured GFP tagged SKMEL19 cells with dermal fibroblasts. After treatment with 
PLX4032, expression of the IGF-1R on the cell surface of melanoma cells was analyzed by 
FACS. We found that co-cultivation of SKMEL19 melanoma cells with human primary dermal 
fibroblasts slightly increases surface expression of the IGF-1R (Figure 19A and 19C), but did 
not activate MAPK signaling (Figure 19E). More importantly, whereas PLX4032 treatment of 
melanoma cells reduced surface IGF-1R expression as shown before, co-cultivation of 
melanoma cells with primary fibroblasts resulted in a significantly reduced down-regulation of 
the IGF-1R after PLX4032 treatment (Figure 19A and 19C). This effect is cell-cell contact 
dependent and not mediated by fibroblast-derived soluble factors because we do not see the 
effect when we inhibit cell-cell contact by co-culture in a Boyden chamber (Figure 19B). 
Moreover, the effect was less pronounced on RNA level suggesting again a 
posttranscriptional mechanism (Figure 19D). These data indicate that cell-cell contact of 
human melanoma cells with dermal fibroblasts stabilizes IGF-1R surface expression. 
Interestingly, co-cultivation of melanoma cells with human primary fibroblasts not only in 
monolayer (Figure 19F) but also in 3-dimensional spheroids (Figure 19H) enhanced 
significantly the resistance towards PLX4032 treatment in melanoma cells. The increased 
resistance is partly mediated by the IGF-1R as seen after down-regulation of IGF-1R by 
siRNA in the monolayer culture system (Figure 19G). These data indicate that primary 
human fibroblasts are able to stabilize IGF-1R expression on melanoma cells by cell-cell 
contact and confer enhanced resistance towards PLX4032. 
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Figure 19: Dermal fibroblasts mediate up-regulation of the IGF-1R by cell-cell contact and increase 
therapy resistance.  
(A, B) The surface expression of IGF1R in GFP-expressing SKMEL19 melanoma cells by flow-cytometric 
analyses. In (A), the cells were pre-cultivated for 24 hours with primary human dermal fibroblasts (FM) or not 
(MM), and then were either untreated or treated with PLX4032 (1 µM) for additional 24 hours. In (B), 
Co-cultivation was done in Boyden chambers to inhibit fibroblast-melanoma cell contact, but which allowed 
secreted factors to reach their targets. After 24 hours of co-cultivation, the cells were either untreated or treated 
for 24 hours with PLX4032 (1 µM). Filled grey field denotes isotype control staining. (C) 3x10
4 
SKMEL19 
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 elano a cells were cultured alone or with fi ro last on fi ronectin coated (50 μg/ l) cha  er slides overnight, 
and then were treated with  LX4032 (2 μ ) for 24 hours. After that, the Cells were fixed and stained using 
anti-IGF-1R (blue), HMB45 (red) for the detection of melanocytic cells, and analysed using a confocal 
laser-scanning microscope. Nuclei were stained with YOPRO (green).  (D) Shown is relative mRNA expression 
of IGF1R. Cells were treated as in (A), harvested and prepared for qRT-PCR. For statistics Two-way ANOVA 
analysis has been done. (E) The cytoplasmic pERK in GFP-expressing SKMEL19 melanoma cells by 
flow-cytometric analyses. The cells were pre-cultivated for 24 hours with primary human dermal fibroblasts (FM) 
or not (MM), and then were either untreated or treated with PLX4032 (1 µM) for additional 24 hours. (F, G) The 
cell viability of GFP-expressing SKMEL19 melanoma cells was assessed by measuring fluorescence intensity 
using a fluorometer. In (F), the melanoma cells were either cultured alone (MM) or with primary human dermal 
fibroblasts for 24 hours, and then treated with PLX4032 (1µM or 2µM) for additional 72 hours. Data are 
presented as the mean of relative viability compared to untreated cells set as 1 from triplicate experiments. In 
(G), scramble siRNA or siRNA against IGF-1R was transfected into GFP-expressing SKMEL19. After 24 hours 
of transfection, the cells were cultured alone (MM) or with primary human dermal fibroblasts (FM) for 24 hours, 
and then the cells were treated with PLX4032 (1 µM) for additional 72 hours. Data are presented as the mean of 
relative viability compared to untreated cells set as 1 from triplicate experiments. (H) Shown is a 
three-dimensional spheroid assay. GFP-expressing SKMEL19 melanoma cells alone (M+M) or with primary 
human dermal fibroblasts (F+M) were seeded to form spheroids in 1% Agarose coated 96 well plates, and then 
the spheroids were treated with PLX4032 (10 µM) up to 8 days. PLX4032 was refreshed every 3 days. Cell 
viability was measured by determination of GFP-expressing SKMEL19 melanoma cells using fluorescence 
microscopy.  
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4 Discussion: 
The IGF-1 signaling pathway plays a relevant role in regulating cellular proliferation and 
apoptosis. There is now considerable evidence that the risk of several common cancers 
increases when the level of circulating IGF-1 is high (Pollak, Schernhammer et al. 2004). The 
targeting of IGF-1R by various therapeutic strategies has demonstrated encouraging 
anti-neoplastic activity in laboratory models, which justifies the expansion of clinical trials of 
several novel drug candidates (Pollak, Schernhammer et al. 2004; Riedemann and Macaulay 
2006; Tao, Pinzi et al. 2007). In melanoma, the IGF-1R is overexpressed compared with 
benign naevi (Kanter-Lewensohn, Girnita et al. 2000). IGF-1R antisense oligonucleotides 
have been shown to inhibit melanoma cell survival in vitro and growth of FO-1 melanoma 
xenografts in nude mice (Resnicoff, Coppola et al. 1994). Knockdown of IGF-1R is capable of 
inducing significant survival inhibition and enhancement of apoptosis, regardless of BRAF 
mutation status (Maloney, McLaughlin et al. 2003; Yeh, Bohula et al. 2006; Macaulay, 
Middleton et al. 2013). The importance of IGF-1R expression and activity was stressed again 
in therapy-resistance of malignant melanoma against the BRAFV600E inhibitor PLX4032 
(Villanueva, Vultur et al. 2010). These findings suggest that the IGF-1R is an attractive target 
for melanoma treatment.  
IGF-1R is widely expressed on neoplastic and normal tissues. Although receptor levels in 
cancers are sometimes higher than the levels seen in normal tissues, gene amplification 
associated with large increases in receptor number is rare (Tao, Pinzi et al. 2007; Pollak 
2012). Therefore, understanding the molecular mechanisms regulating IGF-1R expression 
and activity in melanoma cells is indispensable. 
In this study, we show that the expression of IGF-1R is upregulated in melanoma cells. PTEN 
regulates IGF-1R expression mainly on posttranscriptional level in a phosphatase dependent 
manner, and PTEN loss melanoma cells escape IGF-1R blockade by decreased IGF-1R 
expression after treatment with IGF-1R inhibitor. Moreover hyperactivation of BRAF elevates 
IGF-1R expression by increasing its stability. PLX4032 treatment decreases IGF-1R 
expression, which play a relevant role for the inhibitory function of PLX4032. In addition, we 
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also point out that heterocellular contact of melanoma cells with dermal fibroblasts stabilizes 
IGF-1R expression on melanoma cell membrane, which confers melanoma initial resistance 
to PLX4032. 
4.1 IGF-1R expression correlates with expression of PTEN in human melanoma cells  
PTEN is either lost or impaired in up to 30% of melanomas (Teng, Hu et al. 1997; Tsao, Goel 
et al. 2004). Compared to primary melanomas, loss of PTEN expression is mainly found in 
melanoma metastases. It cooperates with the BRAFV600E mutation seen in about half of all 
melanoma samples to promote melanoma metastases formation (Dankort, Curley et al. 
2009). Moreover, as a negative regulator of PI3K/AKT pathway, loss of PTEN leads to 
increased activity of PI3K/AKT pathway (Keniry and Parsons 2008; Aguissa-Toure and Li 
2012). In line with it, we show that loss of PTEN results in higher activity of PI3K/AKT pathway 
than that in PTEN expressing melanoma cells.  
Our results also show a positive correlation of PTEN and IGF-1R expression in several 
human melanoma cell lines already on protein and RNA level. Modulation of PTEN 
expression in PTEN loss and PTEN expressing melanoma cells confirms its direct regulatory 
effect on IGF-1R expression. Further we describe that the regulation of IGF-1R by PTEN is 
not dependent on its negative regulatory function of PI3K activity, which is differ from the 
report in glioblastoma cell lines by Lackey et al.(Lackey, Barnett et al. 2007). It could be due 
to tumor cell-specific mechanisms to modulate IGF-1R expression. Moreover, we 
demonstrated that neither of single nor both phosphatase-deficient mutants are able to 
increase expression of the IGF-1R. Although overexpression of wild-type PTEN is able to 
induce an up to two-fold increase in IGF-1R mRNA expression, this cannot explain the more 
than 7-fold higher protein expression of the IGF-1R. Therefore, our results point out that 
PTEN is able to increase IGF-1R expression in melanoma cells mainly on a 
posttranscriptional level by its lipid and protein phosphatase activity. Further our study shows 
that the stability of the IGF-1R and its pro forms before and after PTEN induction is not 
different. Hence, the PTEN phosphatase-dependent increase in IGF-1R expression in 
melanoma cells is not the result of increased stabilization of the IGF-1R protein. By 
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endocytosis IGF-1R is incorporated into clathrin- or caveolin-coated vesicles, by which the 
IGF-1R is recycled back to the cell surface or degraded by the proteasome and lysosomal 
pathways (Girnita, Girnita et al. 2003; Sehat, Andersson et al. 2007; Sehat, Andersson et al. 
2008). This process is regulated by phospho-tyrosine motifs of IGF-1R (Girnita, Worrall et al. 
2014). As a phosphatase, PTEN possess both lipid phosphatase and protein phosphatase 
activity (Shi, Paluch et al. 2012).  It indicates that PTEN has potential to influence IGF-1R 
recycling by regulating phosphorylation of tyrosine, the signal of internalization, to modulated 
IGF-1R expression. Our results also confirmed that the expression of wild-type PTEN, but not 
of the mutant forms, increased surface expression of the IGF-1R. Therefore our results 
demonstrated that PTEN regulated IGF-1R expression might be achieved by a combination 
of enhanced IGF-1R transcription and increased protein shuttling. 
Interestingly, we also found that over-expression of PTEN in PTEN negative melanoma cell 
lines in a short time does not affect survival and proliferation of melanoma cells contrary to 
what is seen in other tumor systems (Aguissa-Toure and Li 2012). On one side it might be that 
we over-express PTEN using an inducible expression system, which regulates the amount of 
PTEN in such a moderate level that it is less toxic effect to melanoma cells; on the other side 
it might also be that melanoma cells have a better counter-regulatory mechanism than other 
tumor cells due to the constitutive activation of MAPK signaling.  
Interestingly, we show that PTEN expression determines sensitivity toward IGF-1R inhibition. 
Melanoma cells, which had lost PTEN expression and low IGF-1R expression, are more 
resistant to IGF-1R inhibition. In the presence of PTEN, it counteracts the IGF-1R inhibitor 
induced decreased expression of IGF-1R and increases sensitivity toward IGF-1R inhibition. 
IGF-1R inhibitors are used in several clinical trials. Therefore, this finding has important 
therapeutic implications, suggesting that the dose of IGF-1R inhibitor used should be 
adjusted depending on the PTEN expression levels in the tumor.  
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4.2 The regulation of IGF-1R expression is independent on PI3K and AKT activity in 
melanoma cells  
Previous studies found that IGF-1R activity and expression is negative modulated by 
PI3K/AKT pathway activity, which is in part due to mTORC1 inhibition and in part to a 
FOXO-dependent activation of receptor expression (Chandarlapaty, Sawai et al. 2011). Our 
result also shows that IGF-1R expression negatively correlates with activation of PI3K/AKT 
signaling in human melanoma cells. However, we found that transient inhibition of PI3K by 
different inhibitors has no effect on expression of IGF-1R. We also modulated AKT activity by 
modulating AKT3 expression, the dominant isoform in melanoma (Stahl, Sharma et al. 2004). 
As same as inhibition of PI3K, it has also slightly effect on IGF-1R expression. The reason 
why the feedback mechanism doesn´t work in melanoma cells is still elusive. One 
explanation might be that there seems to be tumor cell-specific mechanisms to modulate 
IGF-1R expression. 
4.3 BRAF enhances IGF-1R expression independent on MAPK signaling activity 
A number of novel BRAF or MEK inhibitors have been developed and the most promising 
inhibitors used at the moment in the clinic are PLX4032, which inhibits specifically BRAFV600E, 
and the selective MEK1/2 inhibitors selumetinib (AZD6244, ARRY-142886) and trametinib. 
Phase 1-3 clinical trials of the BRAF kinase inhibitor PLX4032 have shown impressive 
response rates of more than 50% in patients with metastatic melanoma with the BRAFV600E 
mutation (Flaherty, Puzanov et al. 2010; Chapman, Hauschild et al. 2011). However, 
PLX4032-treated melanoma patients rapidly developed therapy resistance within 7 months. 
Therefore understanding the resistance mechanism is necessary. Recently, over-expression 
of the IGF-1R was shown to be a key mechanism conferring secondary resistance towards 
the BRAFV600E inhibitor PLX4032 (Villanueva, Vultur et al. 2010). However another group 
showed that stimulation with IGF-1, the cognate ligand, was not able to protect melanoma 
cells from PLX4032 treatment (Straussman, Morikawa et al. 2012). The paradox results 
suggest that there must be different intrinsic intracellular regulatory mechanisms, by which 
the expression and activity of IGF-1R signalling are regulated in PLX4032 sensitive and 
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resistant melanoma cells. Our results show that inhibition of BRAFV600E by PLX4032 reduced 
IGF-1R expression on transcription and protein level in a MAPK pathway independent 
manner. Moreover localization of IGF-1R on cell membrane surface, where IGF-1R takes its 
function to transduce signals downstream, is also dramatically decreased after PLX4032 
treatment. Furthermore, the evidences that down-regulation of IGF-1R sensitizes melanoma 
cells to PLX4032 treatment, and over-expression of IGF-1R in melanoma cells using 
inducible virus system increases resistance towards PLX4032 treatment, which is enhanced 
by activation of IGF-1R with its ligand IGF-1, stresses that down-regulation of IGF-1R plays a 
key role on the function of PLX4032. In addition, we also confirm that BRAFV600E itself can 
increase stability of IGF-1R and enhance its localization on cell membrane in a MAPK activity 
independent manner. Our results probably confer an explanation to the paradox function of 
IGF-1R in PLX4032 sensitive and resistant melanoma cells. But how the chronic treatment of 
PLX4032 induces IGF-1R over-expression has still to be elucidated. 
4.4 Dermal fibroblasts mediate up-regulation of the IGF-1R by cell-cell contact and 
increase therapy resistance 
Although a few studies show that melanoma cells isolated from PLX4032 resistant patient 
have additional mutation (Johannessen, Boehm et al. 2010; Nazarian, Shi et al. 2010; Shi, 
Hong et al. 2014; Van Allen, Wagle et al. 2014), the main reason for acquired resistance of 
melanoma to PLX4032 treatment is reactivation of MAPK by formation of hetero-dimer of 
BRAF with ARAF or CRAF, or by elevated expression of RTK (Nazarian, Shi et al. 2010; 
Poulikakos and Rosen 2011). It indicates that the origin of resistant melanoma cells are not 
due to drug selection of heterogeneous subpopulation of tumor cells, but due to 
reprogramming of some of melanoma cells surviving from PLX4032 treatment, when 
exposed to PLX4032. Therefore, understanding of the mechanism by which melanoma cells 
acquire initial resistance to PLX4032, give a chance to overcome the resistance of melanoma 
cells to PLX4032 treatment. Recently, one study demonstrated that the transcriptional 
profiles differed in RAF inhibitor-sensitive and inhibitor-resistant BRAFV600-mutant 
melanomas (Konieczkowski, Johannessen et al. 2014). Most drug-sensitive cell lines and 
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patient biopsies showed high expression and activity of the melanocytic lineage transcription 
factor MITF, while intrinsically resistant cell lines and biopsies displayed low MITF expression 
but higher levels of NF-κB signaling and the receptor tyrosine kinase AXL. In addition to 
intrinsic factors, the tumor micro-environment confers innate resistance to therapy (Gkretsi, 
Stylianou et al. 2015). One study showed that the secretion of hepatocyte growth factor 
(HGF) by tumor stromal cells resulted in activation of the HGF receptor (MET), and sequently 
activated the MAPK and PI3K/AKT pathways, thus conferring melanoma cells resistance to 
RAF inhibition (Straussman, Morikawa et al. 2012). It was also showed that melanoma cells 
can recruit and activate fibroblasts, which provide both structural (extracellular matrix 
proteins) and chemical support (growth factors), therefore resulting in melanoma cell growth 
and drug resistance (Flach, Rebecca et al. 2011). In line with it, Hirata et al. showed that 
melanoma-associated fibroblasts stimulate matrix production/remodeling, and, consequently, 
survival signaling in melanoma cells via β1-integrin, Src, and FAK, which can drive resistance 
to the BRAF inhibitor PLX4720 (Hirata, Girotti et al. 2015). Primary fibroblasts mediated initial 
resistance to PLX4032 treatment is also confirmed in our study. Although it showed that 
fibroblast-derived IGF-1 could not mediate resistance towards BRAF inhibition (Nazarian, Shi 
et al. 2010; Villanueva, Vultur et al. 2010; Straussman, Morikawa et al. 2012), interestingly we 
show that primary fibroblasts are able to stabilize IGF-1R expression on the cell surface by 
yet unknown cell-cell interaction. Destruction of heterocellular interaction or down-regulation 
of IGF-1R expression by small interfering siRNA in melanoma cells is able to diminish 
fibroblast mediated PLX4032 resistance. There has been increasing recognition, that integrin 
activation is able to modify the phosphorylation and signaling from the IGF-1R and 
subsequently the biological outcomes (Maile and Clemmons 2002; Ivaska and Heino 2010). 
The O’Connor group described that the RACK1 scaffolding protein, known to interact with β1 
integrin, binds to IGF-1R, and affects Shc/Grb2 downstream signaling (Hermanto, Zong et al. 
2002).  urther, the O’Conner group de onstrated that the mutually exclusive association of 
RACK1 with phosphatase PP2A or β1 integrin is controlled by IGF-1 stimulation (Kiely, 
O'Gorman et al. 2006). Recently, the Takada group further stressed cross-talk between the 
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two pathways, in accord with the co-localization of IGF-1R and integrins together at focal 
adhesion complexes. They found that IGF-1 ligand binds directly to αvβ3 integrin and α6β4 
integrin, thus influencing IGF-1R signaling (Saegusa, Yamaji et al. 2009), including 
sustaining of cells during anchorage independence (Fujita, Ieguchi et al. 2012). The results 
indicate that the interaction of IGF-1R with integrins might be a key regulator for fibroblast 
mediated therapy resistance. But it has to be shown whether melanoma-fibroblast adhesion 
is able to increase IGF-1R stability; whether PTEN is involved in this process; and how 
IGF-1R and its activity influence the signaling mediated by FAK.  
Taken together, according our results we propose the network of IGF1R regulation in 
melanoma as shown in figure 20. Both tumor cell intrinsic mechanisms with IGF-1R 
stabilization by hyperactivation of BRAF and/or PTEN and microenvironmental influences 
with IGF-1R stabilization by melanoma cell-fibroblast contact enhance expression and 
activation of IGF-1R promoting melanoma progression and therapy resistance. 
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Figure 20: Proposed model of the mechanisms regulating IGF-1R expression in melanoma cells. 
IGF-1R is regulated in melanoma cells by a combination of tumor cell intrinsic mechanisms as stabilization of 
the IGF-1R either by hyper-activation of BRAF or probably protein trafficking by PTEN as well as 
micro-environmental heterocellular contacts with fibroblast. Enhanced expression and activation of IGF-1R lead 
to melanoma progression and therapy resistance. 
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5 Outlook 
We showed that PTEN influences IGF-1R expression and by this therapy resistance in 
melanoma. It has still to be solved what are the molecular mechanisms behind this. Further 
we will also investigate if PTEN can influence expression of other RTKs, such as EGFR and 
Met, which play a relevant role in melanoma progression and therapy resistance. Moreover, it 
has still to be solved what are the molecular mechanisms involved in fibroblast-melanoma 
cellular contact induced enhancement of IGF-1R expression. Interestingly, it has been shown 
that the IGF-1R can translocate to the nucleus and auto-regulates its own expression in 
breast cancer cells (Sarfstein, Pasmanik-Chor et al. 2012). Also, nuclear IGF-1R has been 
considered to be involved in a switch in oncogene-induced transformation at advanced 
stages of the disease. In addition, nuclear IGF-1R is complexed with LEF-1/TCF at the 
human cyclin D1 promoter to increase expression of cyclin D1, hence contributing to 
neoplastic transformation. It seems that nuclear IGF-1R may serve as a potential prognostic 
biomarker for successful therapy, therefore it has to be seen whether the IGF-1R is also 
present in the nucleus in melanoma cells and what the clinic relevance it takes.  
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6 Summary 
Among RTKs, the IGF-1R plays a relevant role in cancer development. IGF-1R and its natural 
ligands regulate multiple cellular functions, including cellular proliferation, survival, 
anchorage independent growth, tumor neovascularization, migration, invasion, and 
metastasis. But in clinical settings, the mechanism of aberrant IGF-1R is still not clear: the 
receptor does not show intrinsic receptor abnormalities, and the large increases in receptor 
number are rarely associated with gene amplification (Tao, Pinzi et al. 2007; Pollak 2012). 
Therefore, understanding the molecular mechanisms regulating IGF-1R expression and 
activity in melanoma cells is indispensable. Our study showed that in melanoma cells IGF-1R 
expression is regulated by tumor cell intrinsic mechanisms and that hyperactivation of BRAF 
and the phosphatase activity of PTEN increase IGF-1R expression. Besides this, 
heterocellular contact of melanoma cells with dermal fibroblast stabilizes IGF-1R expression 
on the cell membrane. Enhanced expression and activation of IGF-1R are able to promote 
melanoma therapy resistance against PLX4032 treatment. Interestingly, PTEN-negative 
melanoma cells escape IGF-1R blockade by a downregulation of IGF-1R expression, 
implicating that only in melanoma patients with PTEN-positive tumors treatment with IGF-1R 
inhibitors would be a suitable strategy to combat therapy resistance. Our study emphasizes 
that microenvironmental and tumor cell-intrinsic mechanisms regulate IGF-1R expression 
and thus modulate sensitivity to targeted therapies. 
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Zusammenfassung: 
Der IGF-1R spielt unter den RTKs mit die wichtigste Rolle in der Krebs-Entwicklung. Der 
IGF-1R und seine Liganden regulieren verschiedenste Zellfunktionen, die wesentlich für die 
Entstehung des malignen Phänotyps sind; einschließlich Zellproliferation, Überleben, 
Wachstum unabhängig von Zellkontakthemmung, Tumorneovaskularisierung sowie 
Migration, Invasion und Metastasierung der Tumorzellen. In der Klinik konnte jedoch bisher 
kein klarer Mechanismus von dysreguliertem IGF-1R gefunden werden: Der Rezeptor weist 
keine intrinsische fehlerhafte Veränderung auf und auch eine erhöhte Expression des 
Rezeptors durch Genamplifikation ist äußerst selten. Deshalb ist das  Verständnis der 
molekularen Mechanismen, die die Expression und Aktivität des IGF-1Rs in Melanom-Zellen 
regulieren, unentbehrlich.  
Unsere Studie zeigt, dass die Expression von IGF-1R in Melanomzellen durch einen 
intrinsischen Mechanismus reguliert wird; außerdem spielen die erhöhte Expression des 
IGF-1R durch Hyperaktivierung von BRAF sowie der Phosphatase-Aktivität von PTEN eine 
Rolle. Darüber hinaus stabilisiert der Kontakt von Melanomzellen mit dermalen Fibroblasten 
die Expression von IGF-1R auf deren Zellmembran. Erhöhte Expression und Aktivität von 
IGF-1R können Resistenz gegenüber der Behandlung mit z.B. BRAF-Inhibitoren wie 
PLX4032 vermitteln. Interessanterweise können PTEN-negative Melanomzellen der 
negativen Wirkung der IGF-1R Inhibition durch eine verminderte Expression des IGF-1R 
entgehen. Das bedeutet, dass nur in Melanompatienten mit einem PTEN-positiven Tumor 
die Behandlung mit Hemmstoffen gegen IGF-1R eine passende Strategie darstellt, um die 
Therapieresistenz zu bekämpfen. Unsere Studie hebt hervor, dass das Mikromilieu des 
Tumors und Tumorzell-intrinsische Mechanismen die Expression des IGF-1R regulieren und 
dadurch das Therapieansprechen auf zielgerichtete Hemmstoffe beeinflussen können. 
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